<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:738.6pt;left:485.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#ffffff">Vol.:(0123456789)</span></p>
<p style="top:33.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Drugs (2022) 82:293&#x2013;310 </span></p>
<p style="top:44.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">https://doi.org/10.1007/s40265-021-01668-x</span></p>
<p style="top:65.8pt;left:56.8pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt">SYSTEMATIC REVIEW</span></b></p>
<p style="top:105.8pt;left:51.0pt;line-height:16.0pt"><b><span style="font-family:MyriadPro,serif;font-size:16.0pt">Statins and&#xa0;Gliomas: A&#xa0;Systematic Review of&#xa0;the&#xa0;Preclinical Studies </span></b></p>
<p style="top:123.8pt;left:51.0pt;line-height:16.0pt"><b><span style="font-family:MyriadPro,serif;font-size:16.0pt">and&#xa0;Meta&#x2011;Analysis of&#xa0;the&#xa0;Clinical Literature</span></b></p>
<p style="top:158.4pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Luis&#xa0;F.&#xa0;Rendon</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,2</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; Ishaan&#xa0;A.&#xa0;Tewarie</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,3,4</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> &#xa0;&#xb7; David&#xa0;J.&#xa0;Cote</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,5</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">&#xa0;&#xb7; Aaron&#xa0;Gabriel</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">6</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">&#xa0;&#xb7; Timothy&#xa0;R.&#xa0;Smith</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">&#xa0;&#xb7; </span></b></p>
<p style="top:170.9pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Marike&#xa0;L.&#xa0;D.&#xa0;Broekman</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,3,4</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">&#xa0;&#xb7; Rania&#xa0;A.&#xa0;Mekary</span></b><sup><b><span style="font-family:MyriadPro,serif;font-size:7.0pt">1,6</span></b></sup><b><span style="font-family:MyriadPro,serif;font-size:10.0pt"> </span></b></p>
<p style="top:200.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Accepted: 17 December 2021 / Published online: 5 February 2022 </span></p>
<p style="top:210.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">&#xa9; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022</span></p>
<p style="top:238.7pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Abstract</span></b></p>
<p style="top:251.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Background</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> Gliomas represent most common primary brain tumors. Glioblastoma (GBM) is the most common subtype </span></p>
<p style="top:263.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and carries a poor prognosis. There is growing interest in the anti-glioma properties of statins. The aim of this study was </span></p>
<p style="top:276.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to conduct a systematic review of the preclinical literature and to meta-analyze existing clinical studies to determine what </span></p>
<p style="top:288.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">benefit, if any, statins may confer in the context of glioma.</span></p>
<p style="top:301.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Methods</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> The PubMed, Embase, Cochrane, and Web of Science libraries were queried in May 2021. Preclinical studies were </span></p>
<p style="top:313.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">included if they investigated the anti-cancer effects of statins in glioma in&#xa0;vitro and in&#xa0;vivo. Clinical studies were included </span></p>
<p style="top:326.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">if they reported incidence rates of glioma by statin use, or mortality outcomes among GBM patients by statin use. Pooled </span></p>
<p style="top:338.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">point estimates were calculated using a random-effects model.</span></p>
<p style="top:351.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Results</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> In total, 64 publications, 51 preclinical and 13 clinical, were included. Preclinical studies indicated that statins inhib-</span></p>
<p style="top:363.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ited glioma cell proliferation, migration, and invasion. These effects were time- and concentration-dependent. Synergistic </span></p>
<p style="top:376.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-glioma effects were observed when statins were combined with other anti-cancer therapies. Clinical observational stud-</span></p>
<p style="top:388.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies showed an inverse, albeit non-statistically significant, association between statin use and incidence rate of glioma (HR </span></p>
<p style="top:401.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">= 0.84, 95% CI 0.62&#x2013;1.13, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 72%, p-heterogeneity = 0.003, 6 studies). Statin use was not associated with better overall </span></p>
<p style="top:413.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">survival following GBM surgery (HR = 1.05, 95% CI 0.85&#x2013;1.30, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 30%, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt">-heterogeneity = 0.23, 4 studies).</span></p>
<p style="top:426.2pt;left:51.0pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt">Conclusion</span></b><span style="font-family:STIX,serif;font-size:10.0pt"> Statins were potent anti-cancer drugs that suppressed glioma growth through various mechanisms in&#xa0;vitro; </span></p>
<p style="top:438.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">these effects have translated into the clinical realm, clinically but not statistically, in terms of glioma incidence but not GBM </span></p>
<p style="top:451.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">survival.</span></p>
<p style="top:494.2pt;left:312.5pt;line-height:10.0pt"><b><span style="font-family:MyriadPro,serif;font-size:10.0pt;color:#ffffff">Key Points </span></b></p>
<p style="top:518.8pt;left:312.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The preclinical studies indicate that statins possess </span></p>
<p style="top:531.3pt;left:312.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">potent anti-cancer effects.</span></p>
<p style="top:549.4pt;left:312.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The clinical studies showed a clinically but not statisti-</span></p>
<p style="top:561.9pt;left:312.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cally significant benefit from regular statin use and </span></p>
<p style="top:574.4pt;left:312.9pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">glioma incidence but not GBM survival.</span></p>
<p style="top:646.3pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">1 Introduction</span></b></p>
<p style="top:672.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Glioma is the most common primary brain tumor in adults </span></p>
<p style="top:685.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Glioblastoma (GBM) accounts for 45% of all gliomas </span></p>
<p style="top:697.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and carries a poor prognosis of 15&#x2013;18 months&#x2019; survival </span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,691.6667,93.333339)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAB4AAAAdCAYAAAC9pNwMAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAkklEQVR4nMXDgQpDAABF0fv/X7eZjI0xY5OIRBJ5+4x36iATzvOU
I8dxyJF93+XItm1yZF1XObIsixyZ51mOTNMkR8ZxlCPDMMiRvu/lSNd1cqRtWznS
NI0c+f5+cqSuaznyqSo58i5LOVIUhRx55bkcybJMjjzTVI4kyUOO3ONYjkRRJEdu
YShHguAmRy7Xqxz/9cejFeCVYgAAAAAASUVORK5CYII=">
<p style="top:533.6pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> </span><sup><span style="font-family:STIX,serif;font-size:8.5pt"> </span></sup><sup><span style="font-family:Wingdings,serif;font-size:8.5pt">*</span></sup><sup><span style="font-family:STIX,serif;font-size:8.5pt"> Luis F. Rendon </span></sup></p>
<p style="top:533.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lrendon@bu.edu</span></p>
<p style="top:552.3pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">1</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:553.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Neurosurgery, Computational Neurosciences </span></p>
<p style="top:563.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Outcomes Center, Brigham and&#xa0;Women&#x2019;s Hospital, Harvard </span></p>
<p style="top:573.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Medical School, 75 Francis Street, Boston, MA&#xa0;02115, USA</span></p>
<p style="top:587.3pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">2</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:588.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Neurosurgery, Boston University School </span></p>
<p style="top:598.6pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of&#xa0;Medicine, Boston, MA&#xa0;02118, USA</span></p>
<p style="top:612.3pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">3</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:613.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Neurosurgery, Haaglanden Medical Center, </span></p>
<p style="top:623.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">The&#xa0;Hague, The&#xa0;Netherlands</span></p>
<p style="top:637.4pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">4</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:638.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Neurosurgery, Leiden Medical Center, </span></p>
<p style="top:648.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Leiden, The&#xa0;Netherlands</span></p>
<p style="top:662.4pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">5</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:663.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Neurosurgery, University of&#xa0;Southern </span></p>
<p style="top:673.7pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">California, Los&#xa0;Angeles, CA&#xa0;90033, USA</span></p>
<p style="top:687.4pt;left:51.0pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">6</span><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:688.8pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Department of&#xa0;Pharmaceutical business and&#xa0;administrative </span></p>
<p style="top:698.8pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sciences, School of&#xa0;Pharmacy, MCPHS University, Boston, </span></p>
<p style="top:708.8pt;left:65.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MA&#xa0;02120, USA</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 294</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:57.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Despite efforts to improve therapeutics, the median </span></p>
<p style="top:69.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">survival for GBMs has remained unchanged for nearly </span></p>
<p style="top:82.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">two decades [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">4</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Therefore, it is imperative to inno-</span></p>
<p style="top:94.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">vate new treatments that reduce incidence or improve sur-</span></p>
<p style="top:107.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">vival. However, developing new chemotherapeutic agents </span></p>
<p style="top:119.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">requires demonstrated efficacy and safety in clinical trials, </span></p>
<p style="top:132.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">which is a time-intensive and costly endeavor [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">5</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Drug </span></p>
<p style="top:144.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">repurposing, a process by which an already-approved </span></p>
<p style="top:157.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">drug is used for an indication other than that initially </span></p>
<p style="top:169.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">intended, has gained increasing popularity in oncology </span></p>
<p style="top:182.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">6</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Patients may immediately benefit from approved </span></p>
<p style="top:194.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pharmacotherapies if these treatments are found to reduce </span></p>
<p style="top:207.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">incidence or improve morbidity or mortality for their spe-</span></p>
<p style="top:219.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cific disease [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:232.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Statins block cholesterol synthesis by inhibiting the </span></p>
<p style="top:244.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase </span></p>
<p style="top:257.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">enzyme. They were initially approved to treat hypercho-</span></p>
<p style="top:269.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lesteremia and to prevent coronary artery disease [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">8</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:282.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Recently, statins have also been demonstrated to possess </span></p>
<p style="top:294.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-inflammatory and anti-cancer properties [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">9</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">11</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Inves-</span></p>
<p style="top:307.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tigators are now aiming to validate the use of statins as a </span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">treatment in different primary malignancies, with promising </span></p>
<p style="top:332.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">results in prostate, kidney, and lung cancer [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">19</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Malig-</span></p>
<p style="top:344.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nant glioma cells may be especially sensitive to statin treat-</span></p>
<p style="top:357.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment considering that the mevalonate cascade, the pathway </span></p>
<p style="top:369.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that results in cholesterol synthesis, is often dysregulated in </span></p>
<p style="top:382.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">this cell type [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">19</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">21</span><span style="font-family:STIX,serif;font-size:10.0pt">]. This distinct feature of glioma cells </span></p>
<p style="top:394.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">has inspired both preclinical and clinical studies to explore </span></p>
<p style="top:407.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the use of statins as anti-glioma agents. Our study aimed </span></p>
<p style="top:419.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to systematically review and meta-analyze the existing lit-</span></p>
<p style="top:432.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">erature to determine the association between statin use and </span></p>
<p style="top:444.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">glioma incidence and GBM survival.</span></p>
<p style="top:493.2pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">2  Methods</span></b></p>
<p style="top:519.0pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">2.1  Search Strategy</span></b></p>
<p style="top:544.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The PubMed, Embase, Cochrane, and Web of Science librar-</span></p>
<p style="top:557.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies were searched for relevant studies following the Preferred </span></p>
<p style="top:569.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Reporting Items for Systematic Reviews and Meta-Analyses </span></p>
<p style="top:582.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(PRISMA) guidelines [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">22</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The query was conducted on </span></p>
<p style="top:594.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">May 20, 2021. A professional librarian was consulted to </span></p>
<p style="top:607.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">verify that the search syntax contained all synonyms for gli-</span></p>
<p style="top:619.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">oma, glioma cell lines, and statins. The search syntax can be </span></p>
<p style="top:632.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">found in the Online Appendix. Studies were eligible only if </span></p>
<p style="top:644.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">they were published in English. No restrictions were placed </span></p>
<p style="top:657.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">by the date of publication. Titles and abstracts of relevant </span></p>
<p style="top:669.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies were independently screened by two authors (LFR </span></p>
<p style="top:682.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and AG). Full-text articles were screened by two independ-</span></p>
<p style="top:694.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ent authors (LFR and AG). Any discrepancies were resolved </span></p>
<p style="top:707.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">by a third author (IRT).</span></p>
<p style="top:57.2pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">2.2  Inclusion Criteria and&#xa0;Exclusion Criteria</span></b></p>
<p style="top:83.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Preclinical studies were included if they investigated the </span></p>
<p style="top:95.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-tumor effects of statins on malignant glioma cells, glial </span></p>
<p style="top:108.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tumors, or glioma animal models. Clinical studies were </span></p>
<p style="top:120.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">included if they examined the possible effects statins have </span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on glioma incidence, morbidity, or mortality. Studies focus-</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing on other mevalonate pathway inhibitors, nonglial brain </span></p>
<p style="top:158.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tumors, or nonglial cell lines were excluded. Case reports, </span></p>
<p style="top:170.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies performed in a pediatric population, and reviews </span></p>
<p style="top:183.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were excluded.</span></p>
<p style="top:218.3pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">2.3  Data Extraction</span></b></p>
<p style="top:244.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The following variables were collected from the preclini-</span></p>
<p style="top:256.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cal studies: year of publication, type(s) of statin used, the </span></p>
<p style="top:269.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cell line used, use of adjuvant therapy, effect on prolifera-</span></p>
<p style="top:281.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion, migration, invasion, autophagy, change in tumor size, </span></p>
<p style="top:294.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">method of tumor size assessment, location of tumor place-</span></p>
<p style="top:306.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment, route of statin administration, overall survival (OS), </span></p>
<p style="top:319.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and associated mechanisms. For clinical studies, the fol-</span></p>
<p style="top:331.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lowing variables were collected: year of publication, study </span></p>
<p style="top:344.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">design, type(s) of statin used, sample size, duration and/or </span></p>
<p style="top:356.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">intensity of statin therapy, effect sizes for glioma incidence </span></p>
<p style="top:369.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rate (IR) or OS.</span></p>
<p style="top:404.3pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">2.4  Data Analysis</span></b></p>
<p style="top:430.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Reported hazard ratios (HR) or odds ratios (OR) comparing </span></p>
<p style="top:442.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">participants with the longest statin exposure to the statin </span></p>
<p style="top:455.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">unexposed groups were extracted. Odds ratios derived from </span></p>
<p style="top:467.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">risk set sampling (incidence density sampling) studies were </span></p>
<p style="top:480.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">considered unbiased estimators of HRs [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">23</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Odds ratios </span></p>
<p style="top:492.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">derived from prevalent case control studies (cumulative </span></p>
<p style="top:505.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">incidence sampling) were considered unbiased estimates </span></p>
<p style="top:517.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of the relative risk (RR) under the rare disease assumption </span></p>
<p style="top:530.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(&lt;&#xa0;10%) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">23</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Moreover, the RR was assumed to approxi-</span></p>
<p style="top:542.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mate the HR when the outcome is rare. Therefore, the final </span></p>
<p style="top:555.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">point estimates in the meta-analysis were all converted to </span></p>
<p style="top:567.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">HR. Two analyses were then conducted: (1) a meta-anal-</span></p>
<p style="top:580.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ysis for the incidence rate of glioma by statin use, and (2) </span></p>
<p style="top:592.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a meta-analysis for overall survival in GBM by statin use. </span></p>
<p style="top:605.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">A random-effects model with a DerSimonian-Laird (DL) </span></p>
<p style="top:617.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">estimator was applied in order to obtain the pooled HRs </span></p>
<p style="top:630.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and their estimated 95% confidence intervals (CIs). Forest </span></p>
<p style="top:642.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">plots were generated to depict and summarize the results. </span></p>
<p style="top:655.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Heterogeneity was assessed using the </span><i><span style="font-family:STIX,serif;font-size:10.0pt"> I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> and Cochran&#x2019;s </span><i><span style="font-family:STIX,serif;font-size:10.0pt">Q</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> </span></p>
<p style="top:667.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statistic (</span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt">-value &lt; 0.10). Low heterogeneity was defined </span></p>
<p style="top:680.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">as </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> values between 0 and 25%, moderate heterogeneity </span></p>
<p style="top:692.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">between 25% and 50%, and substantial heterogeneity &gt; 50%. </span></p>
<p style="top:705.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Statistical analysis was conducted in R (Version 3.6.3) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">24</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">295</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">A two-tailed </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt">-value &lt;&#xa0;0.05 was considered statistically sig-</span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nificant unless otherwise indicated.</span></p>
<p style="top:93.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">2.5  Risk of&#xa0;Bias Assessment</span></b></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Study quality was assessed using the Newcastle-Ottawa </span></p>
<p style="top:131.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Quality Assessment Scale for cohort and case control studies </span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">25</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Points were awarded based on the following criteria: </span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">selection (4 maximum points), comparability (2 maximum </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">points), and exposure/outcome (3 maximum points) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">25</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The scores were evaluated in accordance with the Agency </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">for Healthcare Research and Quality (AHRQ) standards </span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Studies with scores &gt;&#xa0;6, 4&#x2013;6, and &lt;4 were deemed </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">as being good quality, fair, and poor quality, respectively </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:STIX,serif;font-size:10.0pt">].&#xa0;&#xa0;Assessment of publication bias was not feasible due </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to the limited number of studies (&lt;&#xa0;10) per outcome [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:279.8pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">3  Results</span></b></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">A total of 7079 unique publications were identified (Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">). </span></p>
<p style="top:318.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">After screening studies based on title and abstract, 180 stud-</span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies were selected for full-text screening. Sixty-four studies, </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">51 preclinical and 13 clinical, met the inclusion criteria </span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Supplementary Table&#xa0;1 and Table&#xa0;3).</span></p>
<p style="top:380.6pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.1  Proliferation</span></b></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Forty preclinical studies examined the role of statins as </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">monotherapy on the proliferation of glioma, all of which </span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">concluded that statins reduce glioma cell proliferation </span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">49</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">59</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">61</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">67</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">69</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The observed reduction of glioma </span></p>
<p style="top:468.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cell was dose- and time-dependent proliferation [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:481.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">49</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">59</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">66</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">69</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:493.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The postulated mechanism was a G0/G1 cell cycle </span></p>
<p style="top:506.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">arrest due to the upregulation of P21, a cell cycle regula-</span></p>
<p style="top:518.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tor [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">6</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:531.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The inhibition of proliferative activity was reversed </span></p>
<p style="top:543.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">by the administration of mevalonate pathway intermedi-</span></p>
<p style="top:556.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ates, namely mevalonate or geranylgeranyl pyrophosphate </span></p>
<p style="top:568.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(GGPP), indicating that the blockage of HMG-CoA reduc-</span></p>
<p style="top:581.4pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tase was specifically responsible for these observations [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:593.9pt;left:51.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">56</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">58</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">66</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">] (Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:618.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.2  Migration and&#xa0;Invasion</span></b></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The effects of statin monotherapy on migration or invasion </span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were reported in 11 preclinical studies (Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">31</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. All studies observed an </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">inhibition of migration [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">31</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Reduced glioma cell invasion was reported in seven [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">] of eight studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Several mechanisms </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were postulated as explanations. First, statins disrupt actin </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">bundles and reduce expression of vimentin, leading to a </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">compromise in the integrity of the cytoskeleton [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Sec-</span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ond, decreases in matrix metalloproteases, specifically </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">MMP-2, MMP-9, and microglial MT1-MMP affected the </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">capacity for cell migration [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Finally, reduced trans-</span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">forming growth factor beta (TGF-&#x3b2;) contributed to changes </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in cellular morphologies that inhibited invasiveness [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Similar to the effects on proliferation, these results occurred </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in a dose- and time-dependent manner and were reversed by </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">GGPP and mevalonate [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:205.6pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.3  Induction of&#xa0;Apoptosis and&#xa0;Autophagy</span></b></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Statin monotherapy was found to induce apoptosis in 32 </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">preclinical studies (Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">32</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The driving </span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mechanism was activation of caspases 3, 7, 8, and 9 [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">32</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">], inhibition of the </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-apoptotic bcl-2 protein, increased levels of the proap-</span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">optotic Bim protein [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">31</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">], and activation of the c-Jun </span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">N-terminal kinases (JNK) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">]. These pathways </span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">culminated in detectable morphological changes reflecting </span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cell death [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Apopto-</span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">sis was induced in a dose- and time-dependent manner [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">32</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:381.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">], and was reversed by administration of meva-</span></p>
<p style="top:393.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lonate or GGPP in 12 studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">55</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:406.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Additionally, statin monotherapy resulted </span></p>
<p style="top:418.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in an upregulated, but incomplete, autophagic process. </span></p>
<p style="top:431.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Higher levels of P62 and LC3B levels reflected increased </span></p>
<p style="top:443.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">autophagosome formation [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">59</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:456.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Notably, fusion of autophagosomes with lysosomes </span></p>
<p style="top:468.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was inhibited, leading to accumulation of partially degraded </span></p>
<p style="top:481.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cargo inside cells [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The altered autophagic process </span></p>
<p style="top:493.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">combined with apoptosis induction were the two main mech-</span></p>
<p style="top:506.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anisms by which statins induced cell death.</span></p>
<p style="top:530.6pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.4  In Vivo Studies</span></b></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Twelve studies examined the effect of statin monother-</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">apy on overall tumor growth or survival in&#xa0;vivo (Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:STIX,serif;font-size:10.0pt">) </span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. No tumor models were pretreated with statins </span></p>
<p style="top:593.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">prior to implantation. Tumor size was decreased in 75% </span></p>
<p style="top:606.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Notably, the reduction of tumor size </span></p>
<p style="top:618.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was more robust when statins were combined with other </span></p>
<p style="top:631.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pharmacotherapies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Five studies reported the </span></p>
<p style="top:643.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">use of orthotopic tumor models, with four administering </span></p>
<p style="top:656.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statins orally and one via intraperitoneal injections [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">67</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:668.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Two studies using orthotopic models and oral </span></p>
<p style="top:681.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statin administration found a decrease in tumor size [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">67</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:693.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Two studies reported an increase in mouse survival </span></p>
<p style="top:706.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with statin monotherapy, one in a cortical glioma model </span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 296</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:643.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with intraperitoneal statin injections and one in a subcu-</span></p>
<p style="top:656.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">taneous glioma model with oral statin treatment [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:668.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">However, two studies, both using cortical glioma models </span></p>
<p style="top:681.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">with oral statin administration, failed to detect a difference </span></p>
<p style="top:693.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in survival [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:643.8pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.5  Synergistic Effects</span></b></p>
<p style="top:669.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The antitumor effects of statins in combination with other </span></p>
<p style="top:682.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">therapies were examined in 29 studies. The other pharma-</span></p>
<p style="top:694.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cotherapies included gefitinib, irinotecan, temozolomide </span></p>
<img style="position:absolute;transform:matrix(.31938765,0,-0,.31849218,1.5059052,12.384216)" src="data:image/jpeg;base64,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">
<p style="top:607.2pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Fig. 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">PRISMA flowchart depicting the study selection process</span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">297</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:60.3pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Statin monotherapy effects </span><i><span style="font-family:STIX,serif;font-size:8.5pt">in vitro</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:77.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author and year</span></p>
<p style="top:77.3pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin used</span></p>
<p style="top:77.3pt;left:240.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Growth conditions</span></p>
<p style="top:77.3pt;left:340.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Proliferation Migration Invasion Apoptosis Autophagy</span></p>
<p style="top:96.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Soma (1991) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">56</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:96.1pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:96.1pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:96.1pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:96.1pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:96.1pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:96.1pt;left:465.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:96.1pt;left:506.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:108.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Soma (1992) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">55</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:108.5pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:108.5pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RPMI 1640, fetal calf </span></p>
<p style="top:118.5pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:108.5pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:108.5pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:108.5pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:108.5pt;left:465.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:108.5pt;left:506.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:131.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jones (1994) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">12</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:131.0pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:131.0pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:131.0pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:131.0pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:131.0pt;left:465.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:131.0pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:143.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Soma (1994) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:143.5pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:143.5pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ham&#x2019;s F10 medium, fetal </span></p>
<p style="top:153.5pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">calf serum, horse serum</span></p>
<p style="top:143.5pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:143.5pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:143.5pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:143.5pt;left:465.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:143.5pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:166.0pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Soma (1995) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:166.0pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:166.0pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ham&#x2019;s F10 medium, fetal </span></p>
<p style="top:176.0pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">calf serum, horse serum</span></p>
<p style="top:166.0pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:166.0pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:166.0pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:166.0pt;left:465.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:166.0pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:188.4pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prasanna (1996) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">49</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:188.4pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:188.4pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RPMI 1640, fetal calf </span></p>
<p style="top:198.4pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:188.4pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:188.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:188.4pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:188.4pt;left:465.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:188.4pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:210.9pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kikuchi (1997) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">66</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:210.9pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:210.9pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:210.9pt;left:340.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:210.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:210.9pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:210.9pt;left:465.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:210.9pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:223.4pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Choi (1999) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:223.4pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:223.4pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:223.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:223.4pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:223.4pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:223.4pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:235.9pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Murakami (2001) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:235.9pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:235.9pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Agar, fetal calf serum</span></p>
<p style="top:235.9pt;left:340.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:235.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:235.9pt;left:430.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:235.9pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:235.9pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:248.3pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Schmidt (2001) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:248.3pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:248.3pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:248.3pt;left:340.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:248.3pt;left:389.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:248.3pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:248.3pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:248.3pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:260.8pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Obara (2002) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:260.8pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cerivastatin</span></p>
<p style="top:260.8pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:260.8pt;left:389.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:260.8pt;left:429.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:260.8pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:260.8pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:273.3pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gliemroth (2003) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">35</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:273.3pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:273.3pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:273.3pt;left:389.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:273.3pt;left:429.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:273.3pt;left:465.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:273.3pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:285.8pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jiang (2004)&#xa0;[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">47</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:285.8pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:285.8pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM, fetal bovine serum</span></p>
<p style="top:285.8pt;left:340.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:285.8pt;left:389.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:285.8pt;left:429.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:285.8pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:285.8pt;left:505.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:298.2pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Koyuturk (2004) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:298.2pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:298.2pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:298.2pt;left:389.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:298.2pt;left:429.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:298.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:298.2pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:310.7pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Rattan (2006) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:310.7pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:310.7pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:310.7pt;left:389.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:310.7pt;left:429.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:310.7pt;left:465.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:310.7pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:323.2pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yao (2006) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">61</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:323.2pt;left:151.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:323.2pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RPMI 1640, fetal bovine </span></p>
<p style="top:333.2pt;left:246.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:323.2pt;left:340.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:323.2pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:323.2pt;left:429.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:323.2pt;left:465.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:323.2pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:345.7pt;left:50.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cemeus (2008) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:345.7pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:345.7pt;left:240.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:345.7pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:345.7pt;left:429.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:345.7pt;left:465.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:345.7pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:358.2pt;left:50.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Chan (2008) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:358.2pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:358.2pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:358.2pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:358.2pt;left:429.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:358.2pt;left:465.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:358.2pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:370.6pt;left:50.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gabrys (2008) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:370.6pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:370.6pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM with Earle&#x2019;s Bal-</span></p>
<p style="top:380.6pt;left:246.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">anced Salts</span></p>
<p style="top:370.6pt;left:340.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:370.6pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:370.6pt;left:429.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:370.6pt;left:465.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:370.6pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:393.1pt;left:50.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bababeygy (2009) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:393.1pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:393.1pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:393.1pt;left:340.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:393.1pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:393.1pt;left:429.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:393.1pt;left:465.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:393.1pt;left:505.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:405.6pt;left:50.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tsuboi (2009) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">59</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:405.6pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pitavastatin</span></p>
<p style="top:405.6pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM, fetal bovine serum</span></p>
<p style="top:405.6pt;left:340.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:405.6pt;left:389.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:405.6pt;left:429.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:405.6pt;left:464.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:405.6pt;left:505.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:418.1pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Wu (2009) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:418.1pt;left:151.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:418.1pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:418.1pt;left:389.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:418.1pt;left:429.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:418.1pt;left:464.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:418.1pt;left:505.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:430.5pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tapia-Perez (2011) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">58</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:430.5pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Various</span></p>
<p style="top:430.5pt;left:240.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM with Earle&#x2019;s Bal-</span></p>
<p style="top:440.5pt;left:246.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">anced Salts, RPMI, fetal </span></p>
<p style="top:450.5pt;left:246.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">calf serum</span></p>
<p style="top:430.5pt;left:340.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:430.5pt;left:389.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:430.5pt;left:429.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:430.5pt;left:464.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:430.5pt;left:505.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:463.0pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yanae (2011) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:463.0pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Various</span></p>
<p style="top:463.0pt;left:240.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:463.0pt;left:340.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:463.0pt;left:389.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:463.0pt;left:429.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:463.0pt;left:464.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:463.0pt;left:505.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:475.5pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Misirkic (2012) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:475.5pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:475.5pt;left:240.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RPMI 1640, fetal bovine </span></p>
<p style="top:485.5pt;left:246.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:475.5pt;left:340.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:475.5pt;left:389.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:475.5pt;left:429.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:475.5pt;left:464.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:475.5pt;left:505.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:498.0pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Yongjun (2013) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:498.0pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:498.0pt;left:240.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine </span></p>
<p style="top:508.0pt;left:246.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Serum</span></p>
<p style="top:498.0pt;left:340.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:498.0pt;left:389.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:498.0pt;left:429.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:498.0pt;left:464.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:498.0pt;left:505.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:520.4pt;left:50.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jiang (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:520.4pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pitavastatin, cerivastatin Human recombinant EGF, </span></p>
<p style="top:530.4pt;left:246.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bFGF, heparin</span></p>
<p style="top:520.4pt;left:340.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:520.4pt;left:389.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:520.4pt;left:429.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:520.4pt;left:464.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:520.4pt;left:505.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:542.9pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jiang (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:542.9pt;left:151.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Various</span></p>
<p style="top:542.9pt;left:240.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:542.9pt;left:389.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:542.9pt;left:429.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:542.9pt;left:464.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:542.9pt;left:505.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:555.4pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kula (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">67</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:555.4pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:555.4pt;left:240.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf Serum</span></p>
<p style="top:555.4pt;left:340.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:555.4pt;left:389.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:555.4pt;left:429.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:555.4pt;left:464.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:555.4pt;left:505.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:567.9pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Slawinska-Brych (2014) </span></p>
<p style="top:577.9pt;left:56.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:567.9pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fluvastatin</span></p>
<p style="top:567.9pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:567.9pt;left:389.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:567.9pt;left:429.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:567.9pt;left:464.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:567.9pt;left:505.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:590.3pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Afshordel (2015) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">28</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:590.3pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:590.3pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:590.3pt;left:340.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:590.3pt;left:389.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:590.3pt;left:429.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:590.3pt;left:464.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:590.3pt;left:505.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:602.8pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bayat (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">31</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:602.8pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:602.8pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:602.8pt;left:389.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:602.8pt;left:429.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:602.8pt;left:464.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:602.8pt;left:505.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:615.3pt;left:50.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fan (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">46</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:615.3pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pitavastatin</span></p>
<p style="top:615.3pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:615.3pt;left:389.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:615.3pt;left:429.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:615.3pt;left:464.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:615.3pt;left:505.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:627.8pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tapia-Perez (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:627.8pt;left:151.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin, lovastatin</span></p>
<p style="top:627.8pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal calf serum</span></p>
<p style="top:627.8pt;left:340.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:627.8pt;left:389.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:627.8pt;left:429.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:627.8pt;left:464.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:627.8pt;left:505.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:640.3pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Alizadeh (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:640.3pt;left:151.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:640.3pt;left:240.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:640.3pt;left:389.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:640.3pt;left:429.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:640.3pt;left:464.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:640.3pt;left:505.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:652.7pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Chang (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:652.7pt;left:151.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fluvastatin, lovastatin</span></p>
<p style="top:652.7pt;left:240.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:652.7pt;left:389.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:652.7pt;left:429.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:652.7pt;left:464.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:652.7pt;left:505.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:665.2pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Liu (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:665.2pt;left:151.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:665.2pt;left:240.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:665.2pt;left:389.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:665.2pt;left:429.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:665.2pt;left:464.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:665.2pt;left:505.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:677.7pt;left:50.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Wang (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:677.7pt;left:151.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:677.7pt;left:240.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neurobasal medium, </span></p>
<p style="top:687.7pt;left:246.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bFGF, EGF</span></p>
<p style="top:677.7pt;left:340.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:677.7pt;left:389.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:677.6pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:677.6pt;left:465.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:677.6pt;left:506.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 298</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:262.7pt;left:51.0pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">DMEM</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> Dulbecco&#x2019;s modified Eagle&#x2019;s medium, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">MEM</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> minimal essential media, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">bFGF</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> basic fibroblast growth factor, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">EGF</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> epidermal growth fac-</span></p>
<p style="top:272.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tor</span></p>
<p style="top:285.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x = study did not investigate effect, </span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> = dcreased effect with statin therapy, &#x2013; = no effect observed with statin therapy, </span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> = increased effect with </span></p>
<p style="top:295.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">statin therapy</span></p>
<p style="top:57.3pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 1  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:73.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author and year</span></p>
<p style="top:73.6pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin used</span></p>
<p style="top:73.6pt;left:240.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Growth conditions</span></p>
<p style="top:73.6pt;left:340.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Proliferation Migration Invasion Apoptosis Autophagy</span></p>
<p style="top:92.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bayat (2018) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">31</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:92.0pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:92.0pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DEMEM-F12, fetal bovine </span></p>
<p style="top:102.0pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:92.0pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:92.0pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:92.0pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:92.0pt;left:465.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:92.0pt;left:506.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:114.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bayat (2018) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">32</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:114.5pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:114.5pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:114.5pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:114.5pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:114.5pt;left:465.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:114.5pt;left:506.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:127.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Beckwitt (2018) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">33</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:127.0pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Various</span></p>
<p style="top:127.0pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RPMI 1640, GlutaMax </span></p>
<p style="top:137.0pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">supplement, fetal bovine </span></p>
<p style="top:147.0pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:127.0pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:127.0pt;left:389.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:127.0pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:127.0pt;left:465.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:127.0pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:159.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oliveira (2018) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:159.5pt;left:151.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:159.5pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM-F12, fetal bovine </span></p>
<p style="top:169.5pt;left:246.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">serum</span></p>
<p style="top:159.5pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:159.5pt;left:389.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:159.5pt;left:430.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:159.5pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:159.5pt;left:506.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:181.9pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Xiao (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:181.9pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:181.9pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM, fetal bovine serum</span></p>
<p style="top:181.9pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:181.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:181.9pt;left:430.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:181.9pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:181.9pt;left:506.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:194.4pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Zhu (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:194.4pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:194.4pt;left:240.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MEM, fetal bovine serum</span></p>
<p style="top:194.4pt;left:340.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:194.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:194.4pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:194.4pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:194.4pt;left:506.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:206.9pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">L&#xfc;etbow (2020) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">48</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:206.9pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:206.9pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:206.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:206.9pt;left:430.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:206.9pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:206.9pt;left:506.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:219.4pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Samiei (2020) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:219.4pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:219.4pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:219.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:219.4pt;left:430.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:219.4pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:219.4pt;left:506.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:231.8pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Shojaei (2020) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:231.8pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:231.8pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum x</span></p>
<p style="top:231.8pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:231.8pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:231.8pt;left:465.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:231.8pt;left:505.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:244.4pt;left:50.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Dastghaib (2020) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:244.4pt;left:151.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:244.4pt;left:240.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">DMEM, fetal bovine serum</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> &#x2193;</span></p>
<p style="top:244.4pt;left:389.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:244.4pt;left:430.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:244.4pt;left:465.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:244.4pt;left:505.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:363.7pt;left:50.8pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Fig. 2  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Diagram summarizing </span></p>
<p style="top:373.7pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the signaling pathways impacted </span></p>
<p style="top:383.7pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">by statin administration. The &#x22a5; </span></p>
<p style="top:393.7pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">symbol indicates an inhibitory </span></p>
<p style="top:403.7pt;left:50.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">action</span></p>
<img style="position:absolute;transform:matrix(.3199096,0,-0,.31979535,-208.65152,7.246216)" src="data:image/jpeg;base64,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">


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">299</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(TMZ), tumor necrosis factor (TNF)-related apoptosis-</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">inducing ligand (TRAIL), and thiazolidinediones, among </span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">others [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Overall, combination therapies </span></p>
<p style="top:618.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were more effective compared to statin monotherapies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:631.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">]. A notable synergistic effect on cell pro-</span></p>
<p style="top:643.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">liferation, migration, and apoptosis was observed when </span></p>
<p style="top:656.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statins were used in combination with TMZ [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:668.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">60</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">69</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Three studies examined statins in combi-</span></p>
<p style="top:681.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nation with radiation, two of which found no added ben-</span></p>
<p style="top:693.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">efit from concurrent treatment [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The other study </span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reported an increase in radiation-induced cell death and </span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">relative survival [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">59</span><span style="font-family:STIX,serif;font-size:10.0pt">] (see Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:STIX,serif;font-size:10.0pt">).</span></p>
<p style="top:618.0pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.6  Meta&#x2011;Analysis: Incidence Rate of&#xa0;Glioma</span></b></p>
<p style="top:643.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Six studies including 6912 cases of glioma and 729,335 </span></p>
<p style="top:656.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">controls investigated the association between statin use and </span></p>
<p style="top:668.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the incidence rate of glioma (Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">4</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Three </span></p>
<p style="top:681.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies reported ORs that were approximated to HRs due to </span></p>
<p style="top:693.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">risk set sampling methodology [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">77</span><span style="font-family:STIX,serif;font-size:10.0pt">], one reported an </span></p>
<p style="top:706.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">OR, which was approximated to RR under the rare disease </span></p>
<p style="top:60.3pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 2  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Statin monotherapy effects in&#xa0;vivo</span></p>
<p style="top:542.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x = study did not investigate effect, </span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span><span style="font-family:STIX,serif;font-size:8.5pt"> = decreased effect with statin therapy, &#x2013; = no effect observed with statin therapy, </span><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span><span style="font-family:STIX,serif;font-size:8.5pt"> = increased effect with </span></p>
<p style="top:552.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">statin therapy</span></p>
<p style="top:77.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author</span></p>
<p style="top:77.3pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin used</span></p>
<p style="top:77.3pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor placement</span></p>
<p style="top:77.3pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Route of statin admin-</span></p>
<p style="top:87.3pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration</span></p>
<p style="top:77.3pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Method for tumor size </span></p>
<p style="top:87.3pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">assessment</span></p>
<p style="top:77.3pt;left:473.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor size Mouse </span></p>
<p style="top:87.3pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sur-</span></p>
<p style="top:97.3pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">vival</span></p>
<p style="top:116.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kikuchi (1997) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">66</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:116.0pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:116.0pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:116.0pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intratumor injection</span></p>
<p style="top:116.0pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor size = (length </span></p>
<p style="top:126.0pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#xd7; width)</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">1/2</span></sup></p>
<p style="top:116.0pt;left:473.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:116.0pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:138.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Murakami (2001) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:138.5pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:138.5pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:138.5pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Spray, injection</span></p>
<p style="top:138.5pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:148.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:158.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.5</span></p>
<p style="top:138.5pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:138.5pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:171.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gabrys (2008) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:171.0pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:171.0pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:171.0pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intraperitoneal</span></p>
<p style="top:171.0pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:181.0pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:191.0pt;left:395.6pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">&#x3c0;</span></i><span style="font-family:STIX,serif;font-size:8.5pt">/6</span></p>
<p style="top:171.0pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:171.0pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:203.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bababeygy (2009) </span></p>
<p style="top:213.5pt;left:57.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">71</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:203.5pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:203.5pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Orthotopic</span></p>
<p style="top:203.5pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral</span></p>
<p style="top:203.5pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor size was </span></p>
<p style="top:213.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">determined using </span></p>
<p style="top:223.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Advanced PCI soft-</span></p>
<p style="top:233.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ware with sections </span></p>
<p style="top:243.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of brain stained with </span></p>
<p style="top:253.5pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">crystal violet</span></p>
<p style="top:203.5pt;left:473.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:203.5pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:265.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jiang (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:265.9pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pitavastatin, cerivas-</span></p>
<p style="top:275.9pt;left:141.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin</span></p>
<p style="top:265.9pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:265.9pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intraperitoneal</span></p>
<p style="top:265.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:275.9pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:285.9pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.5. Tumors dis-</span></p>
<p style="top:295.9pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sected and weighed </span></p>
<p style="top:305.9pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">after sacrifice</span></p>
<p style="top:265.9pt;left:473.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:265.9pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:318.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Jiang (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:318.4pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Various</span></p>
<p style="top:318.4pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:318.4pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral, intraperitoneal</span></p>
<p style="top:318.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor size meas-</span></p>
<p style="top:328.4pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ured every 2 days, </span></p>
<p style="top:338.4pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">extracted and </span></p>
<p style="top:348.4pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">weighed after sac-</span></p>
<p style="top:358.4pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rifice.</span></p>
<p style="top:318.4pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:318.4pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:370.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kula (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">67</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:370.9pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:370.9pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Orthotopic</span></p>
<p style="top:370.9pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral</span></p>
<p style="top:370.9pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumors dissected and </span></p>
<p style="top:380.9pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">weighed on day 18</span></p>
<p style="top:370.9pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:370.9pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:393.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tapia-Perez (2016) </span></p>
<p style="top:403.3pt;left:57.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:393.4pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin, Lovas-</span></p>
<p style="top:403.3pt;left:141.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin</span></p>
<p style="top:393.4pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Orthotopic</span></p>
<p style="top:393.4pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral</span></p>
<p style="top:393.4pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:403.3pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:413.4pt;left:395.6pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">&#x3c0;</span></i><span style="font-family:STIX,serif;font-size:8.5pt">/6</span></p>
<p style="top:393.4pt;left:473.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:393.4pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;</span></p>
<p style="top:425.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Liu (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:425.8pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin</span></p>
<p style="top:425.8pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:425.8pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intraperitoneal or peri-</span></p>
<p style="top:435.8pt;left:310.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tumoral injection</span></p>
<p style="top:425.8pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:435.8pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:445.8pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.5</span></p>
<p style="top:425.8pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:425.8pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:458.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Peng (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">69</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:458.3pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:458.3pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Subcutaneous</span></p>
<p style="top:458.3pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral</span></p>
<p style="top:458.3pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor volume = </span></p>
<p style="top:468.3pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">length &#xd7;  width</span><sup><span style="font-family:STIX,serif;font-size:5.9pt">2</span></sup><span style="font-family:STIX,serif;font-size:8.5pt"> &#xd7; </span></p>
<p style="top:478.3pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.5236</span></p>
<p style="top:458.3pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:458.3pt;left:518.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">x</span></p>
<p style="top:490.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Wang (2017) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:490.8pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:490.8pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Orthotopic</span></p>
<p style="top:490.8pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Intraperitoneal</span></p>
<p style="top:490.8pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Histologically</span></p>
<p style="top:490.8pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:490.8pt;left:518.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>
<p style="top:503.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Xiao (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:503.3pt;left:135.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin</span></p>
<p style="top:503.3pt;left:220.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Orthotopic, subcuta-</span></p>
<p style="top:513.3pt;left:226.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neous</span></p>
<p style="top:503.3pt;left:304.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Oral</span></p>
<p style="top:503.3pt;left:389.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumors extracted </span></p>
<p style="top:513.3pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and weighed after </span></p>
<p style="top:523.3pt;left:395.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sacrifice</span></p>
<p style="top:503.3pt;left:473.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2193;</span></p>
<p style="top:503.3pt;left:518.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#x2191;</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 300</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:708.8pt;left:51.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 3  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Characteristics of the clinical studies</span></p>
<p style="top:708.8pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author (year)</span></p>
<p style="top:633.7pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study design</span></p>
<p style="top:557.0pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statins used</span></p>
<p style="top:461.2pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study </span></p>
<p style="top:461.2pt;left:78.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">population</span></p>
<p style="top:416.3pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study duration </span></p>
<p style="top:416.3pt;left:78.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(MM/YY)</span></p>
<p style="top:341.5pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin exposure </span></p>
<p style="top:341.5pt;left:78.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ascertainment </span></p>
<p style="top:341.5pt;left:88.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">method</span></p>
<p style="top:266.0pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Primary outcome(s) % Male</span></p>
<p style="top:117.7pt;left:68.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Average </span></p>
<p style="top:117.7pt;left:78.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">age&#xa0;&#xa0;(years)</span></p>
<p style="top:708.8pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ferris (2012) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cumu-</span></p>
<p style="top:627.7pt;left:117.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lative case&#x2013;control</span></p>
<p style="top:557.0pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, lovastatin, </span></p>
<p style="top:551.0pt;left:117.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">atorvastatin, rosuvas-</span></p>
<p style="top:551.0pt;left:127.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin</span></p>
<p style="top:461.2pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">917</span></p>
<p style="top:416.3pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">07/2007 &#x2013; 01/2010</span></p>
<p style="top:341.5pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Patient question-</span></p>
<p style="top:335.5pt;left:117.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">naire</span></p>
<p style="top:266.0pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.5pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">51%</span></p>
<p style="top:117.7pt;left:107.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">56 (mean)</span></p>
<p style="top:708.8pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gaist (2013) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:627.7pt;left:149.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:627.7pt;left:159.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:627.7pt;left:169.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span></p>
<p style="top:557.0pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, lovastatin, </span></p>
<p style="top:551.0pt;left:149.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fluvastatin, atorvastatin, </span></p>
<p style="top:551.0pt;left:159.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cerivastatin, pravastatin, </span></p>
<p style="top:551.0pt;left:169.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin</span></p>
<p style="top:461.1pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">21,136</span></p>
<p style="top:416.3pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/2000 &#x2013; 12/2009</span></p>
<p style="top:341.5pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">National registry</span></p>
<p style="top:266.0pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.5pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">62%</span></p>
<p style="top:117.7pt;left:139.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&lt;&#xa0;60: 11,634</span></p>
<p style="top:117.7pt;left:149.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&gt;&#xa0;60: 9502</span></p>
<p style="top:708.8pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gaist (2014) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">82</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cohort Atorvastatin, cerivastatin,</span></p>
<p style="top:557.0pt;left:192.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fluvastatin, lovastatin,</span></p>
<p style="top:557.0pt;left:202.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pravastatin, simvastatin, </span></p>
<p style="top:551.0pt;left:212.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin</span></p>
<p style="top:461.1pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">339</span></p>
<p style="top:416.3pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/2000&#x2013;12/2009</span></p>
<p style="top:341.5pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">National Registry</span></p>
<p style="top:266.0pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">OS</span></p>
<p style="top:191.5pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">53%</span></p>
<p style="top:117.7pt;left:182.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">67 (mean)</span></p>
<p style="top:708.7pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mohebbi (2014) </span></p>
<p style="top:702.7pt;left:234.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">87</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">RCT </span></p>
<p style="top:557.0pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:461.1pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">42</span></p>
<p style="top:416.2pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">03/2011&#x2013;12/2012</span></p>
<p style="top:341.5pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Double-blind </span></p>
<p style="top:335.5pt;left:234.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">administration</span></p>
<p style="top:266.0pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Plasma MMP-9</span></p>
<p style="top:191.4pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">60%</span></p>
<p style="top:117.7pt;left:224.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">54 (mean)</span></p>
<p style="top:708.7pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Bhavsar (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:8.5pt">] Retrospective cohort Atorvastatin (43.6%), </span></p>
<p style="top:551.0pt;left:257.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">simvastatin (29.5%), </span></p>
<p style="top:551.0pt;left:267.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin (14.1%&apos;), </span></p>
<p style="top:551.0pt;left:277.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pravastatin (10.3%), </span></p>
<p style="top:551.0pt;left:287.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lovastatin (2.5%)</span></p>
<p style="top:461.1pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">284</span></p>
<p style="top:416.2pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1/2006&#x2013;7/2015</span></p>
<p style="top:341.5pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Electronic Medical </span></p>
<p style="top:335.5pt;left:257.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Records</span></p>
<p style="top:266.0pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">OS, PFS</span></p>
<p style="top:191.4pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">40%</span></p>
<p style="top:117.7pt;left:247.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">56 (mean)</span></p>
<p style="top:708.7pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Chen (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.6pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:627.6pt;left:309.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:627.6pt;left:319.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:627.6pt;left:329.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span></p>
<p style="top:557.0pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin, pravastatin, </span></p>
<p style="top:551.0pt;left:309.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin, fluvastatin,</span></p>
<p style="top:557.0pt;left:319.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">simvastatin, atorvastatin</span></p>
<p style="top:461.1pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1,065</span></p>
<p style="top:416.2pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/1996&#x2013;12/2011</span></p>
<p style="top:341.5pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">National registry</span></p>
<p style="top:266.0pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.4pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">51%</span></p>
<p style="top:117.7pt;left:299.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">66 (mean)</span></p>
<p style="top:708.7pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Seliger (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">77</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.6pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:627.6pt;left:352.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:627.6pt;left:362.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:627.6pt;left:372.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span></p>
<p style="top:557.0pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, atorvastatin, </span></p>
<p style="top:551.0pt;left:352.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pravastatin, fluvastatin, </span></p>
<p style="top:551.0pt;left:362.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin</span></p>
<p style="top:461.1pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">27,159</span></p>
<p style="top:416.2pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/1995&#x2013;12/2015</span></p>
<p style="top:341.4pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">National registry</span></p>
<p style="top:266.0pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.4pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">55%</span></p>
<p style="top:117.7pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">55</span></p>
<p style="top:708.7pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Happold (2018) </span></p>
<p style="top:702.7pt;left:394.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">83</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.6pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cohort NA</span></p>
<p style="top:461.1pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">810</span></p>
<p style="top:416.2pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CENTRIC: </span></p>
<p style="top:410.2pt;left:394.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">10/2008&#x2013;05/2011</span></p>
<p style="top:416.2pt;left:404.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CORE: 02/2009 </span></p>
<p style="top:410.2pt;left:414.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&#x2013;8/2013</span></p>
<p style="top:341.4pt;left:384.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Electronic Medical </span></p>
<p style="top:335.4pt;left:394.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Records</span></p>
<p style="top:266.0pt;left:384.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">OS, PFS</span></p>
<p style="top:191.4pt;left:384.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">55%</span></p>
<p style="top:117.7pt;left:384.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">57 (median)</span></p>
<p style="top:708.7pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Seliger (2018) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.6pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cohort Simvastatin, atorvastatin, </span></p>
<p style="top:550.9pt;left:437.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cerivastatin, fluvastatin, </span></p>
<p style="top:550.9pt;left:447.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lovastatin, pravastatin</span></p>
<p style="top:461.1pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1093</span></p>
<p style="top:416.2pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/1998&#x2013;12/2013</span></p>
<p style="top:341.4pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Electronic Medical </span></p>
<p style="top:335.4pt;left:437.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Records</span></p>
<p style="top:265.9pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">OS, PFS</span></p>
<p style="top:191.4pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">57%</span></p>
<p style="top:117.7pt;left:427.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">59 (mean)</span></p>
<p style="top:708.7pt;left:459.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cote (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.6pt;left:458.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective  cohort</span><span style="font-family:STIX,serif;font-size:5.9pt">a</span></p>
<p style="top:557.0pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin, lovastatin, </span></p>
<p style="top:551.0pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pravastatin, rosuvasta-</span></p>
<p style="top:551.0pt;left:479.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tin, simvastatin</span></p>
<p style="top:461.2pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHS: </span></p>
<p style="top:455.2pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">114,419</span></p>
<p style="top:416.3pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHS: 01/1994&#x2013;</span></p>
<p style="top:410.3pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">12/2013</span></p>
<p style="top:341.5pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Patient question-</span></p>
<p style="top:335.5pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">naire</span></p>
<p style="top:266.0pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.5pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHS: 0%</span></p>
<p style="top:191.5pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHSII: 0%</span></p>
<p style="top:191.5pt;left:479.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">HPFS: 100%</span></p>
<p style="top:117.8pt;left:459.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHS: 61 (mean)</span></p>
<p style="top:117.8pt;left:469.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHSII: 45 (mean)</span></p>
<p style="top:117.8pt;left:479.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">HPFS: 58 (mean)</span></p>
<p style="top:461.2pt;left:482.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHSII: </span></p>
<p style="top:455.2pt;left:492.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">115,813</span></p>
<p style="top:416.3pt;left:482.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NHSII: 01/1999&#x2013;</span></p>
<p style="top:410.3pt;left:492.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">12/2013</span></p>
<p style="top:461.2pt;left:504.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">HPFS: </span></p>
<p style="top:455.2pt;left:514.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">50,223</span></p>
<p style="top:416.3pt;left:504.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">HPFS: 01/1990&#x2013;</span></p>
<p style="top:410.3pt;left:514.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">12/2016</span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">301</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">assumption [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">], and two reported HRs [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">78</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The RR </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">was approximated to HR under the rare disease assump-</span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion as well. Upon contact, the authors of one paper [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:10.0pt">] </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">recalculated a multivariable-adjusted HR after exclusion of </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">patients with a history of cancer diagnoses at baseline to </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">be in homogeneity with the original studies included in the </span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">meta-analysis and was hence included in our meta-analysis. </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Pooled results showed that statin users had a non-statistically </span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">significant lower incidence rate of glioma (HR = 0.84, 95% </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">CI 0.62&#x2013;1.13, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 72%, p-heterogeneity = 0.003, 6 stud-</span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies) compared to non-users (Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">]. A sensi-</span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tivity analysis where only studies with a duration of statin </span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">therapy exceeding &#x2265;10 life-time prescriptions or &gt;&#xa0;2 years </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">also revealed a similar non-statistically significant inverse </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">association with glioma incidence rate (HR = 0.76, 95% CI </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">0.51&#x2013;1.15, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 75%, p-heterogeneity = 0.003; 5 studies) </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">77</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:268.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">With regard to GBM, one study reported no association </span></p>
<p style="top:281.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">between &#x2265;&#xa0;2-year statin use and incidence rate of GBM (no </span></p>
<p style="top:293.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">point estimate provided) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">] compared to non-users, while </span></p>
<p style="top:306.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">another reported an increased incidence rate of GBM in ever </span></p>
<p style="top:318.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statin users (HR = 1.57, 95% CI 1.10&#x2013;2.07) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:10.0pt">] compared </span></p>
<p style="top:331.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to never users. Three of the four case control studies were </span></p>
<p style="top:343.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">scored as being of good quality [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">77</span><span style="font-family:STIX,serif;font-size:10.0pt">], with the Ferris </span></p>
<p style="top:356.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">et&#xa0;al. [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">] being assessed as fair quality. Both Cote et&#xa0;al. [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">78</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:368.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:10.0pt">] cohort papers were determined to be of good quality </span></p>
<p style="top:381.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(Supplementary Table&#xa0;1 and Table&#xa0;2).</span></p>
<p style="top:405.6pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.7  Meta&#x2011;analysis: Statins and&#xa0;Survival in&#xa0;GBM</span></b></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Overall survival with statin therapy in GBM was examined </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in four studies (Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">5</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:10.0pt">]. A total of 539 deaths </span></p>
<p style="top:456.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">occurred in 714 patients [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">83</span><span style="font-family:STIX,serif;font-size:10.0pt">]. One study did not provide </span></p>
<p style="top:468.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the number of deaths [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Compared to non-users, statin </span></p>
<p style="top:481.4pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users had a non-statistically significant worse overall sur-</span></p>
<p style="top:493.9pt;left:306.2pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">vival (HR = 1.05, 95% CI 0.85&#x2013;1.30, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">I</span></i><sup><span style="font-family:STIX,serif;font-size:7.0pt">2</span></sup><span style="font-family:STIX,serif;font-size:10.0pt"> = 44%, p-heteroge-</span></p>
<p style="top:506.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">neity = 0.14, four studies, Fig.&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">4</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Low heterogene-</span></p>
<p style="top:518.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ity was present. The four studies were determined to be of </span></p>
<p style="top:531.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">good quality (Supplementary Table&#xa0;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:STIX,serif;font-size:10.0pt">) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:543.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Notably, of the studies that were not included in this </span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">meta-analysis, one reported for OS an HR of 1.20 (95% CI </span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">0.70&#x2013;2.06) in statin users [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">85</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Those results were limited </span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to patients with small postoperative residual tumor volumes </span></p>
<p style="top:593.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">who did not receive adjuvant therapy [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">85</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Another paper </span></p>
<p style="top:606.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reported no association between statin use and median OS </span></p>
<p style="top:618.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in GBM (19.9 months for incident users vs 19.6 months for </span></p>
<p style="top:631.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nonusers, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.98), but used controls that were independent </span></p>
<p style="top:643.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of their study and was, therefore, excluded from the meta-</span></p>
<p style="top:656.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">analysis [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Two studies additionally found no difference </span></p>
<p style="top:668.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in progression-free survival between experimental and con-</span></p>
<p style="top:681.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trol groups (7.6 months in incident users vs 7.8 months in </span></p>
<p style="top:693.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nonusers, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.35, and HR = 1.08, 95% CI 0.83&#x2013;1.41, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = </span></p>
<p style="top:706.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">0.75) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">83</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:708.8pt;left:48.7pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 3  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">(continued)</span></p>
<p style="top:708.8pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author (year)</span></p>
<p style="top:633.7pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study design</span></p>
<p style="top:557.0pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statins used</span></p>
<p style="top:461.2pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study </span></p>
<p style="top:461.2pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">population</span></p>
<p style="top:416.3pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Study duration </span></p>
<p style="top:416.3pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(MM/YY)</span></p>
<p style="top:341.5pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin exposure </span></p>
<p style="top:341.5pt;left:75.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ascertainment </span></p>
<p style="top:341.5pt;left:85.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">method</span></p>
<p style="top:266.0pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Primary outcome(s) % Male</span></p>
<p style="top:117.7pt;left:65.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Average </span></p>
<p style="top:117.7pt;left:74.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">age&#xa0;&#xa0;(years)</span></p>
<p style="top:708.8pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Henker (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">85</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cohort Simvastatin (85%), </span></p>
<p style="top:551.0pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pravastatin (10%), ator-</span></p>
<p style="top:551.0pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">vastatin (5%)</span></p>
<p style="top:461.2pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">224</span></p>
<p style="top:416.3pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/2009&#x2013;12/2016</span></p>
<p style="top:341.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></p>
<p style="top:266.0pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Clinical and radio-</span></p>
<p style="top:260.0pt;left:113.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">logical features </span></p>
<p style="top:260.0pt;left:123.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of epileptogenic </span></p>
<p style="top:260.0pt;left:133.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tumors</span></p>
<p style="top:191.5pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">55%</span></p>
<p style="top:117.7pt;left:103.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">66 (mean)</span></p>
<p style="top:708.8pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Altwairgi (2020) </span></p>
<p style="top:702.8pt;left:155.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">[</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective cohort</span></p>
<p style="top:557.0pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin</span></p>
<p style="top:461.1pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">36</span></p>
<p style="top:416.3pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/2014&#x2013;01/2017</span></p>
<p style="top:341.5pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective admin-</span></p>
<p style="top:335.5pt;left:155.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">istration</span></p>
<p style="top:266.0pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">OS, PFS</span></p>
<p style="top:191.5pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">62%</span></p>
<p style="top:117.7pt;left:145.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">52 (median)</span></p>
<p style="top:708.8pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cote (2021) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">78</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:633.7pt;left:167.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective  cohort</span><span style="font-family:STIX,serif;font-size:5.9pt">b</span></p>
<p style="top:557.0pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></p>
<p style="top:461.2pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">405,515</span></p>
<p style="top:416.3pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">01/2006-12/2016</span></p>
<p style="top:341.5pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Patient question-</span></p>
<p style="top:335.5pt;left:178.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">naire</span></p>
<p style="top:266.0pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></p>
<p style="top:191.5pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">62%</span></p>
<p style="top:117.8pt;left:168.4pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">61 (median)</span></p>
<p style="top:708.8pt;left:196.8pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">IR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> incidence rate, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">OS</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> overall survival, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">PFS</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> progression-free survival, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> not available</span></p>
<p style="top:710.8pt;left:208.8pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">a</span><span style="font-family:STIX,serif;font-size:8.5pt"> Study combined three previously defined cohorts: Nurses&#x2019; Health Study, Nurses&#x2019; Health Study II, Health Professionals Follow-Up Study.</span></p>
<p style="top:710.8pt;left:221.6pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">b</span><span style="font-family:STIX,serif;font-size:8.5pt"> Study used the UK Biobank population-based cohort</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 302</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:707.7pt;left:89.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 4  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">List of clinical studies included in the incidence rate (hazard) of glioma by statin use meta-analysis.</span></p>
<p style="top:707.7pt;left:446.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effect sizes and corresponding 95% confidence Intervals are those reported directly in the study</span></p>
<p style="top:707.7pt;left:459.5pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">OR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> odds ratio, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">HR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> hazard ratio, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">CI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> confidence interval, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">BMI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> body mass index, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> not available,&#xa0;</span><i><span style="font-family:STIX,serif;font-size:8.5pt">No.</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> number</span></p>
<p style="top:709.8pt;left:471.5pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">a</span><span style="font-family:STIX,serif;font-size:8.5pt"> In the cumulative case control study design, the odds ratio is a valid estimate of the relative risk when the disease is rare (&lt;&#xa0;10%)</span></p>
<p style="top:709.8pt;left:484.3pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">b</span><span style="font-family:STIX,serif;font-size:8.5pt"> In the risk set sampling and matched case&#x2013;control studies, the odds ratio is an unbiased estimate of the hazard ratio</span></p>
<p style="top:709.8pt;left:497.2pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">c</span><span style="font-family:STIX,serif;font-size:8.5pt"> HR has been updated to exclude baseline cancers to improve homogeneity of included studies and, therefore, does not match published HR exactly</span></p>
<p style="top:707.7pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">First author and year Study design</span></p>
<p style="top:549.3pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statins used</span></p>
<p style="top:467.8pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">No. glioma </span></p>
<p style="top:467.8pt;left:116.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cases</span></p>
<p style="top:419.9pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">No. controls</span></p>
<p style="top:365.3pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin duration or </span></p>
<p style="top:365.3pt;left:116.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">intensity in meta-</span></p>
<p style="top:365.3pt;left:126.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">analysis</span></p>
<p style="top:299.3pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effect size (OR/</span></p>
<p style="top:299.3pt;left:116.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">HR) (95% CI)</span></p>
<p style="top:231.3pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Variables matched or </span></p>
<p style="top:231.3pt;left:116.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">adjusted for</span></p>
<p style="top:129.3pt;left:106.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Conclusions</span></p>
<p style="top:707.7pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ferris (2012) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective cumu-</span></p>
<p style="top:624.8pt;left:154.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lative case&#x2013;control</span><span style="font-family:STIX,serif;font-size:5.9pt">a</span></p>
<p style="top:549.3pt;left:144.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, lovas-</span></p>
<p style="top:543.3pt;left:154.9pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin, atorvastatin, </span></p>
<p style="top:543.3pt;left:164.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin</span></p>
<p style="top:467.8pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">517</span></p>
<p style="top:419.8pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">400</span></p>
<p style="top:365.3pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&gt;120 months</span></p>
<p style="top:299.2pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.44 (0.15&#x2013;0.97)</span></p>
<p style="top:231.3pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Age, gender, ethnicity, </span></p>
<p style="top:225.3pt;left:154.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">educational level, NSAID </span></p>
<p style="top:225.3pt;left:164.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use, study center</span></p>
<p style="top:129.3pt;left:144.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Long-term statin use is </span></p>
<p style="top:123.3pt;left:154.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">inversely associated </span></p>
<p style="top:123.3pt;left:164.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with glioma</span></p>
<p style="top:707.7pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Gaist (2013) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:624.8pt;left:187.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:624.8pt;left:197.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:624.8pt;left:206.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span><span style="font-family:STIX,serif;font-size:5.9pt">b</span></p>
<p style="top:549.3pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, lovas-</span></p>
<p style="top:543.3pt;left:187.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin, fluvastatin, </span></p>
<p style="top:543.3pt;left:197.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">atorvastatin, ceriv-</span></p>
<p style="top:543.3pt;left:207.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">astatin, pravastatin, </span></p>
<p style="top:543.3pt;left:217.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin</span></p>
<p style="top:467.8pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2656</span></p>
<p style="top:419.8pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">18,480</span></p>
<p style="top:365.3pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">5+ years</span></p>
<p style="top:299.2pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.76 (0.59&#x2013;0.98)</span></p>
<p style="top:231.3pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Birth year, sex, year of </span></p>
<p style="top:225.3pt;left:187.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">index, years of schooling, </span></p>
<p style="top:225.3pt;left:197.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">diabetes, stroke, aspirin, </span></p>
<p style="top:225.3pt;left:207.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NSAID use</span></p>
<p style="top:129.3pt;left:177.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Long-term statin use is </span></p>
<p style="top:123.3pt;left:187.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">inversely associated </span></p>
<p style="top:123.3pt;left:197.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with risk of glioma</span></p>
<p style="top:707.7pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Chen&#xa0; (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:624.8pt;left:239.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:624.8pt;left:249.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:624.8pt;left:259.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span><span style="font-family:STIX,serif;font-size:5.9pt">b</span></p>
<p style="top:549.3pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin, pravas-</span></p>
<p style="top:543.3pt;left:239.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin, rosuvastatin, </span></p>
<p style="top:543.3pt;left:249.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fluvastatin, simvas-</span></p>
<p style="top:543.3pt;left:259.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin, atorvastatin&#xa0;</span></p>
<p style="top:467.8pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">213</span></p>
<p style="top:419.8pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">852</span></p>
<p style="top:365.3pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&gt;11 Prescrip-</span></p>
<p style="top:359.3pt;left:239.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tions&#xa0;</span></p>
<p style="top:299.2pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.43 (0.21-0.88)&#xa0;</span></p>
<p style="top:231.3pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Age, sex, index date, num-</span></p>
<p style="top:225.3pt;left:239.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ber of hospitalizations, </span></p>
<p style="top:225.3pt;left:249.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">continuing statin users, </span></p>
<p style="top:225.3pt;left:259.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">diabetes, stroke, NSAID </span></p>
<p style="top:225.3pt;left:269.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use, use of lipid lowering </span></p>
<p style="top:225.3pt;left:279.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">drugs&#xa0;</span></p>
<p style="top:129.3pt;left:229.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin use is inversely </span></p>
<p style="top:123.3pt;left:239.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">associated with risk </span></p>
<p style="top:123.3pt;left:249.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of brain cancer&#xa0;</span></p>
<p style="top:707.7pt;left:292.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Seliger (2016) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">77</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:292.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Retrospective </span></p>
<p style="top:624.8pt;left:302.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matched case&#x2013;</span></p>
<p style="top:624.8pt;left:312.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">control (risk-set </span></p>
<p style="top:624.8pt;left:321.5pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sampling)</span><span style="font-family:STIX,serif;font-size:5.9pt">b</span></p>
<p style="top:549.3pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin, atorv-</span></p>
<p style="top:543.3pt;left:302.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">astatin, pavastatin, </span></p>
<p style="top:543.3pt;left:312.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fluvastatin, rosuv-</span></p>
<p style="top:543.3pt;left:322.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">astatin&#xa0;</span></p>
<p style="top:467.8pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2469</span></p>
<p style="top:419.8pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">24,690</span></p>
<p style="top:365.3pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&gt;90 Prescrip-</span></p>
<p style="top:359.3pt;left:302.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tions (~10-20 </span></p>
<p style="top:359.3pt;left:312.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">years use)</span></p>
<p style="top:299.2pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">0.75 (0.48&#x2013;1.17)&#xa0;</span></p>
<p style="top:231.3pt;left:292.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Index date, age, sex, general </span></p>
<p style="top:225.3pt;left:302.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">practice, years in database </span></p>
<p style="top:225.3pt;left:312.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prior to index date, </span></p>
<p style="top:225.3pt;left:322.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ethnicity, BMI, smoking, </span></p>
<p style="top:225.3pt;left:332.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">diabetes, congestive heart </span></p>
<p style="top:225.3pt;left:342.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">failure&#xa0;</span></p>
<p style="top:129.3pt;left:292.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin use is not associ-</span></p>
<p style="top:123.3pt;left:302.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ated with risk of </span></p>
<p style="top:123.3pt;left:312.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">glioma&#xa0;</span></p>
<p style="top:707.7pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cote (2019) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">79</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective cohort</span></p>
<p style="top:549.3pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Atorvastatin, lovas-</span></p>
<p style="top:543.3pt;left:364.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tatin, pravastatin, </span></p>
<p style="top:543.3pt;left:374.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosuvastatin, simv-</span></p>
<p style="top:543.3pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">astatin</span></p>
<p style="top:467.8pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">483</span></p>
<p style="top:419.8pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">279,972</span></p>
<p style="top:365.3pt;left:354.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">&gt;&#xa0;8 years</span></p>
<p style="top:299.2pt;left:354.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1.44 (1.03&#x2013;1.99)</span><span style="font-family:STIX,serif;font-size:5.9pt">c</span></p>
<p style="top:231.3pt;left:354.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Age, hypertension, diabe-</span></p>
<p style="top:225.3pt;left:364.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tes, BMI, smoking status</span></p>
<p style="top:129.3pt;left:354.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Long-term statin use </span></p>
<p style="top:123.3pt;left:364.8pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">may be associated </span></p>
<p style="top:123.3pt;left:374.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with increased risk of </span></p>
<p style="top:123.3pt;left:384.7pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">glioma.</span></p>
<p style="top:707.7pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cote (2021) [</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">78</span><span style="font-family:STIX,serif;font-size:8.5pt">]</span></p>
<p style="top:630.8pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prospective cohort</span></p>
<p style="top:549.3pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></p>
<p style="top:467.8pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">574</span></p>
<p style="top:419.9pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">404,941</span></p>
<p style="top:365.3pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Current use</span></p>
<p style="top:299.2pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1.04 (0.81&#x2013;1.33)</span></p>
<p style="top:231.3pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Age, sex, diabetes, hyper-</span></p>
<p style="top:225.3pt;left:407.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tension, BMI, smoking </span></p>
<p style="top:225.3pt;left:417.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">status, statin use</span></p>
<p style="top:129.3pt;left:397.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">No significant associa-</span></p>
<p style="top:123.3pt;left:407.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion between current </span></p>
<p style="top:123.3pt;left:417.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">statin use and glioma </span></p>
<p style="top:123.3pt;left:427.3pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">risk</span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">303</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">3.8  Statins and&#xa0;Morbidity</span></b></p>
<p style="top:82.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Data support the notion that statins may provide a morbid-</span></p>
<p style="top:94.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ity benefit following GBM surgery. A randomized clinical </span></p>
<p style="top:107.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">trial (RCT) found that administration of atorvastatin led to </span></p>
<p style="top:119.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">improved functioning compared to controls as determined </span></p>
<p style="top:132.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">by Karnofsky performance scale (KPS) improvement two </span></p>
<p style="top:144.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">months following GBM surgery (11.43 increase in statin </span></p>
<p style="top:157.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users vs 4.00 in the placebo group, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.03) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">87</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The same </span></p>
<p style="top:169.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">paper found that MMP-9 concentrations were not different </span></p>
<p style="top:182.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">24 h postoperatively, although significant reductions in the </span></p>
<p style="top:194.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">treated group were detected two weeks after surgery (no </span></p>
<p style="top:207.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">point estimate provided, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = 0.048) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">87</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Lastly, statin intake </span></p>
<p style="top:219.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reduced the&#xa0;occurrence of seizures prior to GBM treatment </span></p>
<p style="top:232.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(OR for non-occurrence = 4.94, 95% CI 1.56&#x2013;15.7, </span><i><span style="font-family:STIX,serif;font-size:10.0pt">p</span></i><span style="font-family:STIX,serif;font-size:10.0pt"> = </span></p>
<p style="top:244.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">0.007) [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:280.6pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">4  Discussion</span></b></p>
<p style="top:307.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Statins are gaining increasing attention as anti-cancer </span></p>
<p style="top:319.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">agents given their newly identified anti-inflammatory and </span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-cancer effects. This systematic review and meta-anal-</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ysis aimed to summarize the current literature regarding </span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the association between statins and pre-clinical and clini-</span></p>
<p style="top:369.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cal outcomes of interest. The preclinical studies supported </span></p>
<p style="top:382.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the notion that statins inhibited proliferation, migration, </span></p>
<p style="top:394.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and invasion of glioma cells in&#xa0;vitro. Statins also induced </span></p>
<p style="top:407.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">apoptosis and autophagy. The clinical studies, on the other </span></p>
<p style="top:419.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hand, did not demonstrate statistically&#xa0;significant associa-</span></p>
<p style="top:432.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tions between long-term statin use and glioma incidence </span></p>
<p style="top:444.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">or survival.</span></p>
<p style="top:457.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The included preclinical studies provide important </span></p>
<p style="top:469.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">insights into the specific effects of modulating cholesterol </span></p>
<p style="top:482.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">synthesis in glioma. The consequences of inhibiting the </span></p>
<p style="top:494.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">HMG-CoA reductase enzyme extend beyond the blockage </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of cholesterol synthesis. Downstream signaling pathways </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">dependent on precursors from the mevalonate cascade (e.g. </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">GPPP) regulate cell cycle arrest [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">6</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">54</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">73</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">], TGF-&#x3b2; activity [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">], synthesis of matrix metalloproteases [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:STIX,serif;font-size:10.0pt">], and </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">activation of caspases [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">32</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">36</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">68</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The reversal of statin&#x2019;s anti-proliferative, anti-</span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">migratory, and anti-apoptotic effects by administration of </span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">isoprenoids (i.e., GPPP) supports the idea that blockage of </span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">HMG-CoA reductase leads to a reduction of isoprenoids. </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">These isoprenoids serve critical functions in the regulation </span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of cell cycle in malignant glioma cells. Although serum-</span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rich growth conditions were used by most studies, three </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were conducted in the absence of serum, and their results </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">were not different with respect to changes in proliferation </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and apoptosis [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">65</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The anticancer effect of statins </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">are therefore not limited to the selection of differentiated </span></p>
<p style="top:268.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">glioma cells and are just as efficacious on glioma stem-like </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cells. Likewise, four studies used tumor cells taken from </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">patient samples instead of established cell lines and those </span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies observed similar anticancer effects of statins [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">49</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">55</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">56</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">74</span><span style="font-family:STIX,serif;font-size:10.0pt">].</span></p>
<p style="top:331.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Through a variety of mechanisms, it appears that </span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statins possess potent anti-cancer properties. The dose- </span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and time-dependent nature of these effects pose an inter-</span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">esting dilemma. For clinically relevant observations, </span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statins must first achieve therapeutic concentrations in the </span></p>
<p style="top:393.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">brain microenvironment for prolonged periods. Potency </span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and lipophilicity are, therefore, the two most important </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">characteristics when selecting statins for glioma treat-</span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ment. According to the DrugBank [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">88</span><span style="font-family:STIX,serif;font-size:10.0pt">], the statins with </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the highest capacity to penetrate the blood-brain barrier </span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">as per their ADMET scores were simvastatin (ADMET </span></p>
<p style="top:468.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">= 0.9422), fluvastatin (ADMET = 0.9382), cerivastatin </span></p>
<p style="top:481.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">(ADMET = 0.9381), pitavastatin (ADMET = 0.9296), and </span></p>
<p style="top:493.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lovastatin (ADMET = 0.9287). Importantly, atorvastatin </span></p>
<p style="top:678.2pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Fig. 3  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Forest plot showing the association between statin use and </span></p>
<p style="top:688.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">incidence rate of glioma. The solid squares represent the point esti-</span></p>
<p style="top:698.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mate of each study with the horizontal lines denoting the 95% CI. </span></p>
<p style="top:708.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">The size of the square is proportional to the relative weight of each </span></p>
<p style="top:678.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">respective study. The center of the diamond is the pooled estimate </span></p>
<p style="top:688.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">using a random effects model and its width reflects the 95% CI. </span><i><span style="font-family:STIX,serif;font-size:8.5pt">CI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:698.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">confidence interval, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">HR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> hazard ratio</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 304</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:708.8pt;left:146.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Table 5  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">List of clinical studies included in the overall survival for GBM by statin use meta-analysis.</span></p>
<p style="top:708.8pt;left:414.6pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Effect sizes and corresponding 95% confidence Intervals are those reported directly in the study</span></p>
<p style="top:708.8pt;left:427.5pt;line-height:8.5pt"><i><span style="font-family:STIX,serif;font-size:8.5pt">HR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> hazard ratio, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">GBM</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> glioblastoma Multiforme, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">OS</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> overall survival, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">CI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> confidence interval, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">BMI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> body mass index, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">MMSE </span></i><span style="font-family:STIX,serif;font-size:8.5pt">Mini-Mental State Exam, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">NA</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> not reported,&#xa0;</span><i><span style="font-family:STIX,serif;font-size:8.5pt">No.</span></i><span style="font-family:STIX,serif;font-size:8.5pt">&#xa0;number</span></p>
<p style="top:710.8pt;left:439.5pt;line-height:5.9pt"><span style="font-family:STIX,serif;font-size:5.9pt">a</span><span style="font-family:STIX,serif;font-size:8.5pt"> Extent of surgery includes gross total and subtotal resections.</span></p>
<p style="top:709.6pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">First author and </span></p>
<p style="top:709.6pt;left:172.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">year</span></p>
<p style="top:654.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Study design</span></p>
<p style="top:586.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Statins used</span></p>
<p style="top:506.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">No. </span></p>
<p style="top:506.2pt;left:172.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">deaths</span></p>
<p style="top:472.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">No. </span></p>
<p style="top:472.2pt;left:172.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">patients</span></p>
<p style="top:439.3pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Adjuvant therapies</span></p>
<p style="top:356.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Duration </span></p>
<p style="top:356.2pt;left:172.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">of statin </span></p>
<p style="top:356.2pt;left:181.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">therapy</span></p>
<p style="top:312.0pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Effect size (HR)</span></p>
<p style="top:312.0pt;left:172.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">(95% CI)</span></p>
<p style="top:252.0pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Variables matched or adjusted for</span></p>
<p style="top:128.2pt;left:163.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Conclusions</span></p>
<p style="top:709.6pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Gaist (2014) </span></p>
<p style="top:703.6pt;left:208.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">[</span><span style="font-family:STIX,serif;font-size:7.5pt;color:#0000ff">82</span><span style="font-family:STIX,serif;font-size:7.5pt">]</span></p>
<p style="top:654.2pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Retrospective cohort Atorvastatin, ceriv-</span></p>
<p style="top:580.2pt;left:208.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">astatin, fluvastatin, </span></p>
<p style="top:580.2pt;left:217.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">lovastatin, pravastatin, </span></p>
<p style="top:580.2pt;left:226.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">simvastatin, rosuv-</span></p>
<p style="top:580.2pt;left:235.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">astatin</span></p>
<p style="top:506.2pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">28</span></p>
<p style="top:472.2pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">29</span></p>
<p style="top:439.3pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Surgery (78.8%)</span></p>
<p style="top:439.3pt;left:208.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Radiation (76.1%)</span></p>
<p style="top:439.3pt;left:217.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Chemotherapy (52.2%)</span></p>
<p style="top:356.2pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">&#x2265; 5 years</span></p>
<p style="top:311.4pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">0.75 (0.47&#x2013;1.20)</span></p>
<p style="top:252.0pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Year of diagnosis, age at diagnosis, </span></p>
<p style="top:246.0pt;left:208.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">gender, Charlson Comorbidity </span></p>
<p style="top:246.0pt;left:217.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Index score, diabetes, hospital </span></p>
<p style="top:246.0pt;left:226.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">contact allergy or asthma, years </span></p>
<p style="top:246.0pt;left:235.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">of schooling, anti-asthma drugs, </span></p>
<p style="top:246.0pt;left:244.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">antihistamines, hormone replace-</span></p>
<p style="top:246.0pt;left:253.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">ment therapy, low dose aspirin use, </span></p>
<p style="top:246.0pt;left:262.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">non-aspirin NSAIDs</span></p>
<p style="top:128.2pt;left:199.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Long-term prediag-</span></p>
<p style="top:122.2pt;left:208.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">nostic statin use is </span></p>
<p style="top:122.2pt;left:217.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">not associated with </span></p>
<p style="top:122.2pt;left:226.4pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">improved OS in GBM</span></p>
<p style="top:709.6pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Bhavsar (2016) </span></p>
<p style="top:703.6pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">[</span><span style="font-family:STIX,serif;font-size:7.5pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:7.5pt">]</span></p>
<p style="top:654.2pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Retrospective cohort Atorvastatin (43.6%), </span></p>
<p style="top:580.2pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">simvastatin (29.5%), </span></p>
<p style="top:580.2pt;left:292.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">rosuvastatin (14.1%), </span></p>
<p style="top:580.2pt;left:301.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">pravastatin (10.3%), </span></p>
<p style="top:580.2pt;left:310.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">lovastatin (2.5%)</span></p>
<p style="top:506.2pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">124</span></p>
<p style="top:472.2pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">134</span></p>
<p style="top:439.3pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Surgery (100%)</span></p>
<p style="top:439.3pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Chemotherapy + radia-</span></p>
<p style="top:433.3pt;left:292.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">tion (96.1%)</span></p>
<p style="top:356.2pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Preoperative </span></p>
<p style="top:350.2pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">use</span></p>
<p style="top:311.4pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">1.14 (0.79&#x2013;1.64)</span></p>
<p style="top:252.0pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Age, BMI, sex, American Society </span></p>
<p style="top:246.0pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">of Anesthesiology (ASA) physical </span></p>
<p style="top:246.0pt;left:292.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">status, preoperative dexamethasone </span></p>
<p style="top:246.0pt;left:301.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">use, adjusted Charlson comorbidity </span></p>
<p style="top:246.0pt;left:310.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">index</span></p>
<p style="top:128.2pt;left:274.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Preoperative statin use </span></p>
<p style="top:122.2pt;left:283.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">is not associated with </span></p>
<p style="top:122.2pt;left:292.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">improved OS in GBM</span></p>
<p style="top:709.6pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Happold (2018) </span></p>
<p style="top:703.6pt;left:330.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">[</span><span style="font-family:STIX,serif;font-size:7.5pt;color:#0000ff">83</span><span style="font-family:STIX,serif;font-size:7.5pt">]</span></p>
<p style="top:654.2pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Retrospective cohort Atorvastatin, fluvastatin, </span></p>
<p style="top:580.2pt;left:330.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">lovastatin, pitavasta-</span></p>
<p style="top:580.2pt;left:339.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">tin, pravastatin, rosuv-</span></p>
<p style="top:580.2pt;left:348.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">astatin, simvastatin</span></p>
<p style="top:506.2pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">387</span></p>
<p style="top:472.2pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">551</span></p>
<p style="top:439.3pt;left:321.1pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Surgery (99.6%)</span><span style="font-family:STIX,serif;font-size:5.2pt">a</span></p>
<p style="top:439.3pt;left:330.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Chemotherapy + radia-</span></p>
<p style="top:433.3pt;left:339.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">tion (100%)</span></p>
<p style="top:356.2pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Ever use</span></p>
<p style="top:311.5pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">1.31 (1.00&#x2013;1.70)</span></p>
<p style="top:252.0pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Protocol treatment, recursive partition-</span></p>
<p style="top:246.0pt;left:330.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">ing analysis, age, extent of surgery, </span></p>
<p style="top:246.0pt;left:339.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">MMSE score, steroid use, MGMT </span></p>
<p style="top:246.0pt;left:348.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">methylation status</span></p>
<p style="top:128.2pt;left:321.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Ever use of statin is </span></p>
<p style="top:122.2pt;left:330.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">not associated with </span></p>
<p style="top:122.2pt;left:339.8pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">improved OS in GBM</span></p>
<p style="top:709.6pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Seliger (2018) </span></p>
<p style="top:703.6pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">[</span><span style="font-family:STIX,serif;font-size:7.5pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:7.5pt">]</span></p>
<p style="top:654.2pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Retrospective cohort Simvastatin, atorvas-</span></p>
<p style="top:580.2pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">tatin, cerivastatin, </span></p>
<p style="top:580.2pt;left:378.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">fluvastatin, lovastatin, </span></p>
<p style="top:580.2pt;left:387.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">pravastatin</span></p>
<p style="top:506.2pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">NA</span></p>
<p style="top:472.2pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">862</span></p>
<p style="top:439.3pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Surgery + radiation + </span></p>
<p style="top:433.3pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">chemotherapy (50.8%)</span></p>
<p style="top:356.2pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Use at time </span></p>
<p style="top:350.2pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">of GBM </span></p>
<p style="top:350.2pt;left:378.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">diagnosis</span></p>
<p style="top:311.5pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">0.96 (0.76&#x2013;1.20)</span></p>
<p style="top:252.0pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Age at diagnosis, sex, year of diagno-</span></p>
<p style="top:246.0pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">sis, BMI, Karnofsky Performance </span></p>
<p style="top:246.0pt;left:378.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Score, Extent of resection, MGMT </span></p>
<p style="top:246.0pt;left:387.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">methylation status, IDH mutation </span></p>
<p style="top:246.0pt;left:396.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">status, primary therapy</span></p>
<p style="top:128.2pt;left:360.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">Statin use at time of </span></p>
<p style="top:122.2pt;left:369.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">diagnosis not associ-</span></p>
<p style="top:122.2pt;left:378.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">ated with improved </span></p>
<p style="top:122.2pt;left:387.6pt;line-height:7.5pt"><span style="font-family:STIX,serif;font-size:7.5pt">OS in GBM</span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">305</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">has an ADMET permeability index of 0.7825 [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">88</span><span style="font-family:STIX,serif;font-size:10.0pt">], while </span></p>
<p style="top:68.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">pravastatin is generally considered to have poor perme-</span></p>
<p style="top:81.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ability through the blood-brain barrier [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">88</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">89</span><span style="font-family:STIX,serif;font-size:10.0pt">]. One study </span></p>
<p style="top:93.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">on human subjects found that the lovastatin concentra-</span></p>
<p style="top:106.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion peaked at 1.3 ng/mL in the cerebrospinal fluid (CSF) </span></p>
<p style="top:118.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">2.5 h after a 40-mg dose of lovastatin [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">90</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Other experi-</span></p>
<p style="top:131.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ments found that the maximum statin concentrations in </span></p>
<p style="top:143.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rodent brains 1 h after oral administration was 600 pmol/g </span></p>
<p style="top:156.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">brain for simvastatin, 300 pmol/g brain for lovastatin, and </span></p>
<p style="top:168.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">100 pmol/g brain for pravastatin, with large reductions in </span></p>
<p style="top:181.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">concentrations observed after 6 and 24 h [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">91</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The exact </span></p>
<p style="top:193.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mechanism by which these reductions occur has not been </span></p>
<p style="top:206.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">described but is likely to be due to metabolism or active </span></p>
<p style="top:218.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">transport of statins out of the central nervous system [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">89</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span></p>
<p style="top:231.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">91</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The concentrations used in the in&#xa0;vitro studies were </span></p>
<p style="top:243.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">appreciably higher, as they commonly ranged from 0.1&#x2013;20 </span></p>
<p style="top:256.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">uM. Therefore, permeability across the blood-brain bar-</span></p>
<p style="top:268.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rier poses a major issue when attempting to translate these </span></p>
<p style="top:281.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">promising preclinical findings into clinical practice as cur-</span></p>
<p style="top:293.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rently approved doses of statins may be inadequate for </span></p>
<p style="top:306.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinically relevant effects.</span></p>
<p style="top:318.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Although in&#xa0;vivo studies demonstrated benefits from sta-</span></p>
<p style="top:331.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tin therapy, specifically in reducing tumor volume, there was </span></p>
<p style="top:343.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">no consensus regarding overall survival benefit in animal </span></p>
<p style="top:356.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">model studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">75</span><span style="font-family:STIX,serif;font-size:10.0pt">]. The different models (cortical vs </span></p>
<p style="top:368.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">subcutaneous) and means of statin administration (oral vs </span></p>
<p style="top:381.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">intraperitoneal) used makes any interpretation of the results </span></p>
<p style="top:393.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">difficult. Ultimately, the unclear survival benefit highlights </span></p>
<p style="top:406.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the inability of statins to function as a stand-alone therapy </span></p>
<p style="top:418.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in glioma. Multiple preclinical studies reported synergis-</span></p>
<p style="top:431.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tic anti-cancer effects of statins when combined with other </span></p>
<p style="top:443.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">chemotherapies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">34</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">70</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">72</span><span style="font-family:STIX,serif;font-size:10.0pt">]. One paper reported </span></p>
<p style="top:456.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">that statins sensitize glioma cells to the cytotoxic effects of </span></p>
<p style="top:468.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">chemotherapy [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Of the approved treatments for GBM, </span></p>
<p style="top:481.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the combination of temozolomide and statins resulted in sig-</span></p>
<p style="top:493.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nificant cytotoxic effects [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">10</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">51</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">60</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">69</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Further </span></p>
<p style="top:506.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in&#xa0;vivo work using cortical glioma models may provide valu-</span></p>
<p style="top:518.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">able insights into the relationship between chemotherapies, </span></p>
<p style="top:531.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">statin administration, and survival.</span></p>
<p style="top:543.9pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The meta-analysis demonstrated a non-statistically sig-</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nificant inverse association between statin use and incidence </span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">rate of glioma [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">]. An important source of limi-</span></p>
<p style="top:581.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tations in the studies included was the lack of distinction </span></p>
<p style="top:593.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">between prevalent users, incident users, or mixed users. </span></p>
<p style="top:606.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Restricting the analysis to prevalent statin users might </span></p>
<p style="top:618.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">exclude patients who died early (depletion of susceptible) </span></p>
<p style="top:631.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and would artificially inflate the observed point estimate </span></p>
<p style="top:643.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">92</span><span style="font-family:STIX,serif;font-size:10.0pt">], as was reported in three studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Addi-</span></p>
<p style="top:656.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tionally, one matched case control study included in the </span></p>
<p style="top:668.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">meta-analysis failed to adjust for the matching variables, </span></p>
<p style="top:681.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">which resulted in selection bias and hence most likely biased </span></p>
<p style="top:693.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the point estimate [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Another problem inherent to these </span></p>
<p style="top:706.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">observational studies is the possibility of unaccounted </span></p>
<p style="top:56.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">time-varying exposure and time-varying confounders [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">93</span><span style="font-family:STIX,serif;font-size:10.0pt">]. </span></p>
<p style="top:68.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Alterations to individual statin regimens in response to </span></p>
<p style="top:81.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">changing HDL, LDL, and total cholesterol levels may mask </span></p>
<p style="top:93.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the true effect size. Moreover, participants who deviate from </span></p>
<p style="top:106.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">their assigned &#x201c;treatment&#x201d; strategy (statin use vs no use) </span></p>
<p style="top:118.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">in the absence of a contraindication should theoretically be </span></p>
<p style="top:131.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">censored, although the effect on the overall point estimate </span></p>
<p style="top:143.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">may be small if few participants change their treatment regi-</span></p>
<p style="top:156.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">men significantly. None of the studies accounted for vari-</span></p>
<p style="top:168.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ances in treatment regimen, contributing to heterogeneity in </span></p>
<p style="top:181.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">derived HRs [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">76</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">80</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Time-varying inverse probability </span></p>
<p style="top:193.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">weights may be of use for adjustment after&#xa0;censoring time-</span></p>
<p style="top:206.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">varying confounding in future studies [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">94</span><span style="font-family:STIX,serif;font-size:10.0pt">]. In the absence </span></p>
<p style="top:218.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of RCTs, the HR reported here reflects level 3A evidence </span></p>
<p style="top:231.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">as defined as a systematic review of case-control studies </span></p>
<p style="top:243.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">95</span><span style="font-family:STIX,serif;font-size:10.0pt">], thereby supporting the need for further well-designed </span></p>
<p style="top:256.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">studies.</span></p>
<p style="top:268.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">This meta-analysis found a worse survival in statin users </span></p>
<p style="top:281.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">compared to non-users in GBM [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">]. However, as in a </span></p>
<p style="top:293.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">previous report [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">96</span><span style="font-family:STIX,serif;font-size:10.0pt">], this result was non-statistically signifi-</span></p>
<p style="top:306.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cant. These studies defined statin users as those &#x201c;prevalent </span></p>
<p style="top:318.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">users&#x201d; who were taking statins prior to their GBM diagnosis </span></p>
<p style="top:331.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">[</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">92</span><span style="font-family:STIX,serif;font-size:10.0pt">]. This could have led to confounding by indica-</span></p>
<p style="top:343.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion, as death due to comorbidities in long-term&#xa0;statin users </span></p>
<p style="top:356.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">compared to non-users during the study period could skew </span></p>
<p style="top:368.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the calculated HRs in favor of non-users. The lack of infor-</span></p>
<p style="top:381.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">mation on duration and dosage of statin therapy prior to </span></p>
<p style="top:393.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">GBM diagnosis adds heterogeneity to the analysis. Addition-</span></p>
<p style="top:406.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ally, the lack of standardized treatment regimens contributes </span></p>
<p style="top:418.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">to the variance in calculated HRs, as different numbers of </span></p>
<p style="top:431.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">patients in each study received surgery, radiotherapy, and/or </span></p>
<p style="top:443.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">chemotherapy [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">92</span><span style="font-family:STIX,serif;font-size:10.0pt">]. People on high-intensity statins </span></p>
<p style="top:456.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">also suffer from significant other comorbidities, which could </span></p>
<p style="top:468.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">have influenced the choice of treatment they received. Only </span></p>
<p style="top:481.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">two studies controlled for the Charlson Comorbidity Index </span></p>
<p style="top:493.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">score; however, neither controlled for IDH or MGMT status, </span></p>
<p style="top:506.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">two critical prognostic factors in GBM [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">81</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">82</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Only one </span></p>
<p style="top:518.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">study controlled for both MGMT and IDH status but did not </span></p>
<p style="top:531.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">account for comorbid conditions between their study popula-</span></p>
<p style="top:543.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tions [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">84</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Given the heterogeneity across these studies, the </span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">HR presented here reflects level 3A evidence, in terms of </span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">hierarchy. A higher level,&#xa0; such as&#xa0;2A, would be a misclassi-</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">fication as such a determination would suggest homogeneity </span></p>
<p style="top:593.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">across the cohort studies included [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">95</span><span style="font-family:STIX,serif;font-size:10.0pt">]. In order to improve </span></p>
<p style="top:606.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the level of evidence and make actionable recommendations </span></p>
<p style="top:618.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">for the use of statins in GBM, future studies must homoge-</span></p>
<p style="top:631.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">nize adjuvant therapies across study populations and control </span></p>
<p style="top:643.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">for known prognostic variables in GBM.</span></p>
<p style="top:656.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">The discrepancy between the preclinical studies and the </span></p>
<p style="top:668.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">overall survival evidence in GBM patients poses an inter-</span></p>
<p style="top:681.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">esting dilemma. One explanation may be that the overall </span></p>
<p style="top:693.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">survival studies did not distinguish results by specific statins. </span></p>
<p style="top:706.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Including statins with poor blood-brain penetration and less </span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 306</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:243.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">potent anti-cancer effects could dilute a true survival benefit. </span></p>
<p style="top:256.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">As previously mentioned, simvastatin is the most promising </span></p>
<p style="top:268.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">candidate given its pharmacodynamic and pharmacokinetic </span></p>
<p style="top:281.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">properties, and focusing future clinical studies around this </span></p>
<p style="top:293.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">drug, and other lipophilic statin with improved blood-brain </span></p>
<p style="top:306.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">barrier penetration, may provide promising results. Another </span></p>
<p style="top:318.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">explanation could be attributed to the retrospective nature </span></p>
<p style="top:331.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">of the studies, as statin dosages could not be maximized. </span></p>
<p style="top:343.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Subtherapeutic concentrations could also mask any potential </span></p>
<p style="top:356.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinical benefit. Finally, future studies subgrouping popula-</span></p>
<p style="top:368.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tions based on glioma grade can also provide much needed </span></p>
<p style="top:381.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clarity. Nonetheless, clinical evidence does indicate that sta-</span></p>
<p style="top:393.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tin use may be associated with improved morbidity in GBM. </span></p>
<p style="top:406.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">Lower rates of pretreatment seizure, higher KPS scores, and </span></p>
<p style="top:418.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">lower MMP-9 plasma concentrations were observed in sta-</span></p>
<p style="top:431.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tin-treated GBM cohorts [</span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">86</span><span style="font-family:STIX,serif;font-size:10.0pt">, </span><span style="font-family:STIX,serif;font-size:10.0pt;color:#0000ff">87</span><span style="font-family:STIX,serif;font-size:10.0pt">]. Continued assessments of </span></p>
<p style="top:443.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">how statins improve quality of life may also help carve out </span></p>
<p style="top:456.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">a role for statin therapy in this disease. Consequently, there </span></p>
<p style="top:468.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">is a discrepancy between the preclinical and clinical litera-</span></p>
<p style="top:481.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ture. Although in&#xa0;vitro and in&#xa0;vivo preclinical studies over-</span></p>
<p style="top:493.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">whelmingly indicate a favorable effect of statin therapy, the </span></p>
<p style="top:506.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">results seem to be limited to well-controlled environments </span></p>
<p style="top:518.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and reflect the efficacy of statin, as opposed to the effective-</span></p>
<p style="top:531.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ness of statin, in an uncontrolled environment captured in </span></p>
<p style="top:543.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the observational studies.</span></p>
<p style="top:556.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">There are several limitations our study. First, the pre-</span></p>
<p style="top:568.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinical studies reported various magnitudes of anti-cancer </span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">effects from statin exposure depending on the cell model </span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">used. While we did not examine the specific cell models and </span></p>
<p style="top:606.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">instead reported overall results, this may be an important </span></p>
<p style="top:618.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">variable to consider when attempting to translate the pre-</span></p>
<p style="top:631.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinical effects into the clinical realm. Second, to determine </span></p>
<p style="top:643.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the effect on incidence rate of glioma, we relied on ORs/</span></p>
<p style="top:656.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">HRs from the longest statin-exposed groups, which may </span></p>
<p style="top:668.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">have increased the heterogeneity of observed effects. Third, </span></p>
<p style="top:681.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">clinical heterogeneity was inevitable across the observa-</span></p>
<p style="top:693.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tional studies. For example, statin dosages were not widely </span></p>
<p style="top:706.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">reported. Despite these limitations, our study is the first to </span></p>
<p style="top:243.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">our knowledge that comprehensively describes the anti-gli-</span></p>
<p style="top:256.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">oma effects of statins in the preclinical and clinical literature </span></p>
<p style="top:268.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and provides valuable insight into the mechanisms that could </span></p>
<p style="top:281.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">underlie these interactions.</span></p>
<p style="top:325.2pt;left:306.1pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">5  Conclusion</span></b></p>
<p style="top:351.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">In preclinical studies, statins were shown to exert potent </span></p>
<p style="top:364.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">anti-glioma effects through different mechanisms stemming </span></p>
<p style="top:376.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">from the inhibition of the mevalonate cascade, resulting in </span></p>
<p style="top:389.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the inhibition of proliferation, migration, invasion, and in </span></p>
<p style="top:401.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">the induction of apoptosis and autophagy as the main anti-</span></p>
<p style="top:414.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">cancer effects. Synergism was observed between statins and </span></p>
<p style="top:426.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">other cancer therapeutics. A meta-analysis of clinical stud-</span></p>
<p style="top:439.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ies showed a non-statistically significant inverse associa-</span></p>
<p style="top:451.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">tion between statin use and incidence rate of glioma and a </span></p>
<p style="top:464.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">non-statistically significant worse overall survival following </span></p>
<p style="top:476.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">GBM surgery. These discrepancies support the need for con-</span></p>
<p style="top:489.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ducting future well-designed comparative studies compris-</span></p>
<p style="top:501.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">ing incident-statin users with standardized treatment dose </span></p>
<p style="top:514.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">and duration along with appropriate control for possible </span></p>
<p style="top:526.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:STIX,serif;font-size:10.0pt">time-varying exposure and confounding.</span></p>
<p style="top:550.4pt;left:306.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Supplementary Information</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The online version contains supplemen-</span></p>
<p style="top:560.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tary material available at </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s40265- 021- 01668-x</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:582.9pt;left:306.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Acknowledgments</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> We thank Jack Hanna for his administrative assis-</span></p>
<p style="top:592.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tance and Elizabeth Jenkins for helping construct the search syntax.</span></p>
<p style="top:615.9pt;left:306.1pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt">Declarations </span></b></p>
<p style="top:640.4pt;left:306.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Funding</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> No external funding was used in the preparation of this manu-</span></p>
<p style="top:650.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">script.This was a non-funded study.</span></p>
<p style="top:675.4pt;left:306.1pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Conflict of Interest</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> Rendon LF, Tewarie IA, Cote DJ, Gabriel A, Smith </span></p>
<p style="top:685.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">TR, Broekman MLD, Mekary RA have no conflicts of interest that are </span></p>
<p style="top:695.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">relevant to the contents of this manuscript.</span></p>
<p style="top:180.9pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Fig. 4  </span></b><span style="font-family:STIX,serif;font-size:8.5pt">Forest plot showing the association between statin use and </span></p>
<p style="top:190.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">overall survival in GBM. The solid squares represent the point esti-</span></p>
<p style="top:200.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mate of each study with the horizontal lines denoting the 95% CI. </span></p>
<p style="top:210.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">The size of the square is proportional to the relative weight of each </span></p>
<p style="top:180.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">respective study. The center of the diamond is the pooled estimate </span></p>
<p style="top:190.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">using a random effects model and its width reflects the 95% CI. </span><i><span style="font-family:STIX,serif;font-size:8.5pt">CI</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> </span></p>
<p style="top:200.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">confidence interval, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">GBM</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> glioblastoma, </span><i><span style="font-family:STIX,serif;font-size:8.5pt">HR</span></i><span style="font-family:STIX,serif;font-size:8.5pt"> hazard ratio</span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">307</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.7pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Ethics approval</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> Not applicable.</span></p>
<p style="top:76.7pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Code availability</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The metafor statistical packages for R are publicly </span></p>
<p style="top:86.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">available.</span></p>
<p style="top:106.6pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Availability of data and material</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The datasets generated during the </span></p>
<p style="top:116.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">current study are publicly available from the individual studies, and </span></p>
<p style="top:126.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the composite dataset used in this paper is available through the cor-</span></p>
<p style="top:136.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">responding author on reasonable request.</span></p>
<p style="top:156.6pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Consent for publication</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> The authors, jointly and severally, give the </span></p>
<p style="top:166.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">publisher the permission to publish the work.</span></p>
<p style="top:186.6pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Consent to participate</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> Not applicable.</span></p>
<p style="top:206.5pt;left:51.0pt;line-height:8.5pt"><b><span style="font-family:MyriadPro,serif;font-size:8.5pt">Authors&#x2019; contributions</span></b><span style="font-family:STIX,serif;font-size:8.5pt"> LFR: conceptualization, data curation, formal </span></p>
<p style="top:216.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">analysis, investigation, methodology, project administration, software, </span></p>
<p style="top:226.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">validation, visualization, writing&#x2014;original draft, writing&#x2014;review and </span></p>
<p style="top:236.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">editing. IAT: conceptualization, methodology, project administration, </span></p>
<p style="top:246.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">supervision, writing&#x2014;original draft, writing&#x2014;review and editing. DJC: </span></p>
<p style="top:256.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">formal analysis, methodology, validation, writing&#x2014;original draft, writ-</span></p>
<p style="top:266.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing&#x2014;review and editing. AG: data curation, formal analysis, investiga-</span></p>
<p style="top:276.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion, methodology, writing&#x2014;original draft. TRS: conceptualization, </span></p>
<p style="top:286.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">project administration, resources, supervision. MLDB: conceptualiza-</span></p>
<p style="top:296.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion, project administration, resources, supervision, writing &#x2013; review </span></p>
<p style="top:306.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and editing. RAM: conceptualization, methodology, project administra-</span></p>
<p style="top:316.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion, resources, supervision, validation, writing&#x2014;review and editing.</span></p>
<p style="top:362.7pt;left:51.0pt;line-height:12.0pt"><b><span style="font-family:MyriadPro,serif;font-size:12.0pt">References</span></b></p>
<p style="top:388.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer </span></p>
<p style="top:398.0pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CE, et&#xa0;al. The epidemiology of glioma in adults: a &#x201c;state of the </span></p>
<p style="top:407.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">science&#x201d; review. Neuro Oncol. 2014;16(7):896&#x2013;913. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:417.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1093/ neuonc/ nou087</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:427.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 2. Lo HW. Targeting Ras-RAF-ERK and its interactive pathways as </span></p>
<p style="top:437.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">a novel therapy for malignant gliomas. Curr Cancer Drug Targets. </span></p>
<p style="top:447.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2010;10(8):840&#x2013;8. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 2174/ 15680 09107 93357 970</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:457.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 3. Venur VA, Peereboom DM, Ahluwalia MS. Current medical </span></p>
<p style="top:467.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">treatment of Glioblastoma. Cancer Treat Res. 2015;163:103&#x2013;15. </span></p>
<p style="top:477.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ 978-3- 319- 12048-5_7</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:487.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 4. Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the </span></p>
<p style="top:497.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">United States improved after Food and Drug Administration </span></p>
<p style="top:507.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">approval of bevacizumab: a population-based analysis. Cancer. </span></p>
<p style="top:517.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2013;119(19):3489&#x2013;95. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ cncr. 28259</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:527.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 5. Williams CT. Food and Drug Administration Drug Approval </span></p>
<p style="top:537.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Process: A History and Overview. Nurs Clin North Am. </span></p>
<p style="top:547.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2016;51(1):1&#x2013;11. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. cnur. 2015. 10. 007</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:557.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 6. Tewarie IA, Senders JT, Hulsbergen AFC, Kremer S, Broekman </span></p>
<p style="top:567.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MLD. Beta-blockers and glioma: a systematic review of the pre-</span></p>
<p style="top:577.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">clinical and clinical studies. Neurosurg Rev. 2021;44(2):669&#x2013;77. </span></p>
<p style="top:587.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s10143- 020- 01277-4</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:597.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 7. Sleire L, F&#xf8;rde HE, Netland IA, Leiss L, Skeie BS, Enger PO. </span></p>
<p style="top:607.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Drug repurposing in cancer. Pharmacol Res. 2017;124:74&#x2013;91. </span></p>
<p style="top:617.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. phrs. 2017. 07. 013</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:627.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 8. Braun MM, Stevens WA, Barstow CH. Stable Coronary Artery </span></p>
<p style="top:637.9pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Disease: Treatment. Am Fam Physician. 2018;97(6):376&#x2013;84.</span></p>
<p style="top:647.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 9. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin </span></p>
<p style="top:657.8pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cancer Res. 2003;9(1):10&#x2013;9.</span></p>
<p style="top:667.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 10. Oliviera KA, Dal-Cim T, Lopes FG, Ludka FK, Nedel CB, Tasca </span></p>
<p style="top:677.8pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">CI. Atorvastatin promotes cytotoxicity and reduces migration </span></p>
<p style="top:687.8pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and proliferation of human A172 glioma cells. Mol Neurobiol. </span></p>
<p style="top:697.8pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2018;55(2):1509&#x2013;23. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s12035- 017- 0423-8</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:56.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 11. Jakobisiak M, Golab J. Potential antitumor effects of statins </span></p>
<p style="top:66.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">(Review). Int J Oncol. 2003;23(4):1055&#x2013;69.</span></p>
<p style="top:76.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 12. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, </span></p>
<p style="top:86.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0;al. Lovastatin induces growth inhibition and apoptosis in </span></p>
<p style="top:96.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">human malignant glioma cells. Biochem Biophys Res Com-</span></p>
<p style="top:106.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mun. 1994;205(3):1681&#x2013;7. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1006/ bbrc. 1994. </span></p>
<p style="top:116.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2861</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:126.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 13. Koyuturk M, Ersoz M, Altiok N. Simvastatin induces proliferation </span></p>
<p style="top:136.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">inhibition and apoptosis in C6 glioma cells via c-jun N-terminal </span></p>
<p style="top:146.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">kinase. Neurosci Lett. 2004;370(2&#x2013;3):212&#x2013;7. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:156.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1016/j. neulet. 2004. 08. 020</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:166.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 14. Nayan M, Punjani N, Juurlink DN, Finelli A, Austin PC, </span></p>
<p style="top:176.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Kulkarni GS, et&#xa0;al. Statin use and kidney cancer survival out-</span></p>
<p style="top:186.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">comes: a systematic review and meta-analysis. Cancer Treat Rev. </span></p>
<p style="top:196.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2017;52:105&#x2013;16. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. ctrv. 2016. 11. 009</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:206.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 15. Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, </span></p>
<p style="top:216.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Borre M, et&#xa0;al. Postdiagnosis statin use and mortality in Danish </span></p>
<p style="top:226.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">patients with prostate cancer. J Clin Oncol. 2017;35(29):3290&#x2013;7. </span></p>
<p style="top:236.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1200/ JCO. 2016. 71. 8981</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:246.4pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 16. Hung MS, Chen IC, Lee CP, Huang RJ, Chen PC, Tsai YH, </span></p>
<p style="top:256.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0; al. Statin improves survival in patients with EGFR-TKI </span></p>
<p style="top:266.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lung cancer: a nationwide population-based study. PLoS ONE. </span></p>
<p style="top:276.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2017;12(2):e0171137. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1371/ journ al. pone. 01711 </span></p>
<p style="top:286.4pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">37</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:296.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 17. Liu B, Yi Z, Guan X, Zeng YX, Ma F. The relationship between </span></p>
<p style="top:306.4pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">statins and breast cancer prognosis varies by statin type and </span></p>
<p style="top:316.4pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">exposure time: a meta-analysis. Breast Cancer Res Treat. </span></p>
<p style="top:326.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2017;164(1):1&#x2013;11. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s10549- 017- 4246-0</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:336.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 18. Gaist D, Andersen L, Hallas J, S&#xf8;rensen HT, Schr&#xf8;der HD, Friis </span></p>
<p style="top:346.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">S. Use of statins and risk of glioma: a nationwide case&#x2013;control </span></p>
<p style="top:356.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study in Denmark. Br J Cancer. 2013;108(3):715&#x2013;20. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:366.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1038/ bjc. 2012. 536</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:376.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 19. Ahmad F, Sun Q, Patel D, Stommel JM. Cholesterol metabolism: </span></p>
<p style="top:386.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">a potential therapeutic target in Glioblastoma. Cancers (Basel). </span></p>
<p style="top:396.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2019;11(2):146. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3390/ cance rs110 20146</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:406.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 20. Pirmoradi L, Seyfizadeh N, Ghavami S, Zeki AA, Shojaei S. Tar-</span></p>
<p style="top:416.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">geting cholesterol metabolism in glioblastoma: a new therapeutic </span></p>
<p style="top:426.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">approach in cancer therapy. J Investig Med. 2019;67(4):715&#x2013;9. </span></p>
<p style="top:436.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1136/ jim- 2018- 000962</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:446.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 21. Kambach DM, Halim AS, Cauer AG, Sun Q, Tristan CA, Celiku </span></p>
<p style="top:456.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">O. Disabled cell density sensing leads to dysregulated choles-</span></p>
<p style="top:466.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">terol synthesis in glioblastoma. Oncotarget. 2017;8(9):14860&#x2013;75. </span></p>
<p style="top:476.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 18632/ oncot arget. 14740</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:486.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 22. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, </span></p>
<p style="top:496.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cameron C, et&#xa0;al. The PRISMA extension statement for report-</span></p>
<p style="top:506.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing of systematic reviews incorporating network meta-analyses of </span></p>
<p style="top:516.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">health care interventions: checklist and explanations. Ann Intern </span></p>
<p style="top:526.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Med. 2015;162(11):777&#x2013;84. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 7326/ M14- 2385</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:536.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 23. Rothman K, Greenland S, Lash TL. Modern epidemiology. 3rd </span></p>
<p style="top:546.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ed. Lippincott Williams &amp; Wilkins; 2008.</span></p>
<p style="top:556.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 24. R Core Team (2020). R: A language and environment for statisti-</span></p>
<p style="top:566.3pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cal computing. R Foundation for Statistical Computing, Vienna, </span></p>
<p style="top:576.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Austria. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">http:// www.R- proje ct. org/</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:586.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 25. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the </span></p>
<p style="top:596.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">assessment of the quality of nonrandomized studies in metaanaly-</span></p>
<p style="top:606.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ses. Eur J Epidemiol. 2010;25(9):603&#x2013;5.</span></p>
<p style="top:616.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 26. Iswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, </span></p>
<p style="top:626.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">McPheeters M, et&#xa0;al. Assessing the Risk of Bias of Individual </span></p>
<p style="top:636.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Studies in Systematic Reviews of Health Care Interventions. </span></p>
<p style="top:646.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Agency for Healthcare Research and Quality Methods Guide for </span></p>
<p style="top:656.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Comparative Effectiveness Reviews</span><i><span style="font-family:STIX,serif;font-size:8.5pt">. AHRQ Publication</span></i><span style="font-family:STIX,serif;font-size:8.5pt">. 2012 </span></p>
<p style="top:666.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mar 8. No. 12-EHC047-EF. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// effec tiveh ealth care. ahrq. gov/</span><span style="font-family:STIX,serif;font-size:8.5pt">. </span></p>
<p style="top:676.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Accessed 01 Aug&#xa0;2021.</span></p>
<p style="top:686.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 27. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page </span></p>
<p style="top:696.2pt;left:323.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MJ, et&#xa0; al. Cochrane Handbook for Systematic Reviews of </span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 308</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:56.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">interventions. Version 6.2. Cochrane, 2021. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">www. train ing. cochr </span></p>
<p style="top:66.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">ane. org/ handb ook</span><span style="font-family:STIX,serif;font-size:8.5pt">. Accessed 01 Aug&#xa0;2021</span></p>
<p style="top:76.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 28. Afshordel S, Kern B, Clasohm J, K&#xf6;nig H, Priester M, Weis-</span></p>
<p style="top:86.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">senberger J, et&#xa0;al. Lovastatin and perillyl alcohol inhibit glioma </span></p>
<p style="top:96.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cell invasion, migration, and proliferation&#x2013;impact of Ras-/Rho-</span></p>
<p style="top:106.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">prenylation. Pharmarcol Res. 2015;91:69&#x2013;77. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:116.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1016/j. phrs. 2014. 11. 006</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:126.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 29. Alizadeh J, Zeki AA, Mirzaei N, Tewary S, Moghadam AR, </span></p>
<p style="top:136.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Glogowska A, et&#xa0;al. Mevalonate cascade inhibition by simvastatin </span></p>
<p style="top:146.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">induces the intrinsic apoptosis pathway via depletion of isopre-</span></p>
<p style="top:156.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">noids in tumor cells. Sci Rep. 2017;7:44841.&#xa0;Accessed 1 August </span></p>
<p style="top:166.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2021.&#xa0;</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1038/ srep4 4841</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:176.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 30. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, Saberi H, </span></p>
<p style="top:186.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ardakan MMM, Ai A, et&#xa0;al. Anti-inflammatory effects of ator-</span></p>
<p style="top:196.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">vastatin in human glioblastoma spheroids cultured in a three-</span></p>
<p style="top:206.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dimensional model: possible relevance to glioblastoma treatment. </span></p>
<p style="top:216.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Mol Neurobiol. 2018;55(3):2102&#x2013;10. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:226.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s12035- 017- 0445-2</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:236.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 31. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, Saberi H, Taje-</span></p>
<p style="top:246.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rian R, Ardakan MMM, et&#xa0;al. Apoptotic effect of atorvastatin </span></p>
<p style="top:256.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">in glioblastoma spheroids tumor cultured in fibrin gel. Biomed </span></p>
<p style="top:266.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pharmacother. 2016;84:1959&#x2013;19966. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. </span></p>
<p style="top:276.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">biopha. 2016. 11. 003</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:286.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 32. Bayat N, Izadpanah R, Ebrahimi-Barough S, Javidan AN, Ai A, </span></p>
<p style="top:296.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Ardakan MMM, et&#xa0;al. The anti-angiogenic effect of atorvastatin in </span></p>
<p style="top:306.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">glioblastoma spheroids tumor cultured in fibrin gel: in 3D in&#xa0;vitro </span></p>
<p style="top:316.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">model. Asian Pac J Cancer Prev. 2018;19(9):2553&#x2013;60. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:326.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 22034/ APJCP. 2018. 19.9. 2553</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:336.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 33. Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer </span></p>
<p style="top:346.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cell growth and survival, via involvement of Akt signaling. PLoS </span></p>
<p style="top:356.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ONE. 2018;13(5): e0197422. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1371/ journ al. </span></p>
<p style="top:366.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">pone. 01974 22</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:376.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 34. Choi JW, Jung SE. Lovastatin-induced proliferation inhibi-</span></p>
<p style="top:386.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion and apoptosis in C6 glial cells. J Pharmacol Exp Ther. </span></p>
<p style="top:396.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1999;289(1):572&#x2013;9.</span></p>
<p style="top:406.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 35. Gliemroth J, Zulewski H, Arnold H, Terzis AJA. Migration, pro-</span></p>
<p style="top:416.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">liferation, and invasion of human glioma cells following treatment </span></p>
<p style="top:426.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with simvastatin. Neurosurg Rev. 2003;26(2):117&#x2013;24. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:436.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1007/ s10143- 003- 0258-9</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:446.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 36. Misirkic M, Janjetovic K, Vucicevic L, Tovilovic G, Ristic B, </span></p>
<p style="top:456.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Vilimanovich U, et&#xa0;al. Inhibition of AMPK-dependent autophagy </span></p>
<p style="top:466.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">enhances in&#xa0;vitro antiglioma effect of simvastatin. Pharmacol Res. </span></p>
<p style="top:476.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2012;65(1):111&#x2013;9. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. phrs. 2011. 08. 003</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:486.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 37. Obara S, Nakata M, Takeshima H, Kuratsu J, Maruyama I, Kata-</span></p>
<p style="top:496.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">jima I. Inhibition of migration of human glioblastoma cells by </span></p>
<p style="top:506.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cerivastatin in association with focal adhesion kinase (FAK). </span></p>
<p style="top:516.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cancer Lett. 2002;185(2):153&#x2013;61. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/ s0304- </span></p>
<p style="top:526.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">3835(02) 00278-1</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:536.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 38. Slawi&#x144;ska-Brych A, Zdzisi&#x144;ska B, Kandefer-Szersze&#x144; M. Fluv-</span></p>
<p style="top:546.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">astatin inhibits growth and alters the malignant phenotype of the </span></p>
<p style="top:556.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">C6 glioma cell line. Pharmacol Rep. 2014;66(1):121&#x2013;9. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:566.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1016/j. pharep. 2014. 01. 002</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:576.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 39. Soma MR, Baetta R, Bergamaschi S, de Renzis MR, Davegna </span></p>
<p style="top:586.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">C, Battaini F, et&#xa0;al. PKC activity in rat C6 glioma cells: changes </span></p>
<p style="top:596.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">associated with cell cycle and simvastatin treatment. Biochem </span></p>
<p style="top:606.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Biophys Res Commun. 1994;200(2):1143&#x2013;9. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. </span></p>
<p style="top:616.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1006/ bbrc. 1994. 1570</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:626.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 40. Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, et&#xa0;al. Effect of </span></p>
<p style="top:636.4pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">simvastatin on glioma cell proliferation, migration, and apoptosis. </span></p>
<p style="top:646.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neurosurgery. 2009;65(6):1087&#x2013;96. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1227/ 01. </span></p>
<p style="top:656.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">NEU. 00003 60130. 52812. 1D</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:666.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 41. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et&#xa0;al. </span></p>
<p style="top:676.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Statin-induced apoptosis via the suppression of ERK1/2 and Akt </span></p>
<p style="top:686.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">activation by inhibition of the geranylgeranyl-pyrophosphate bio-</span></p>
<p style="top:696.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">synthesis in glioblastoma. J Exp Clin Cancer Res. 2011;30(1):74. </span></p>
<p style="top:706.3pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1186/ 1756- 9966- 30- 74</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:56.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 42. Yongjun Y, Shuyun H, Lei C, Xiangrong C, Zhilin Y, Yiquan </span></p>
<p style="top:66.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">K. Atorvastatin suppresses glioma invasion and migration by </span></p>
<p style="top:76.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reducing microglial MT1-MMP expression. J Neuroimmunol. </span></p>
<p style="top:86.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2013;260(1&#x2013;2):1&#x2013;8. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. jneur oim. 2013. 04. </span></p>
<p style="top:96.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">020</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:106.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 43. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos </span></p>
<p style="top:116.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">J. Lovastatin enhances gefitinib activity in glioblastoma cells </span></p>
<p style="top:126.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">irrespective of EGFRvIII and PTEN status. J Neurooncol. </span></p>
<p style="top:136.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2008;90(1):9&#x2013;17. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s11060- 008- 9627-0</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:146.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 44. Chan DYL, Chen GG, Poon WS, Liu PC. Lovastatin sensi-</span></p>
<p style="top:156.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tized human glioblastoma cells to TRAIL-induced apoptosis. </span></p>
<p style="top:166.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">J Neurooncol. 2008;86(3):273&#x2013;83. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:176.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s11060- 007- 9475-3</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:186.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 45. Chang YL, Huang LC, Chen YC, Wang YW, Hueng DY, Huang </span></p>
<p style="top:196.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">SM. The synergistic effects of valproic acid and fluvastatin on </span></p>
<p style="top:206.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">apoptosis induction in glioblastoma multiforme cell lines. Int J </span></p>
<p style="top:216.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Biochem Cell Biol. 2017;92:155&#x2013;63. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. </span></p>
<p style="top:226.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">biocel. 2017. 10. 003</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:236.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 46. Fan Y, Nguyen DT, Akay Y, Xu F, Akay M. Engineering a </span></p>
<p style="top:246.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">brain cancer chip for high-throughput drug screening. Sci Rep. </span></p>
<p style="top:256.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2016;6:25062. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1038/ srep2 5062</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:266.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 47. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM. Lovasta-</span></p>
<p style="top:276.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tin-induced up-regulation of the BH3-only protein, Bim, and cell </span></p>
<p style="top:286.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">death in glioblastoma cells. J Neurochem. 2004;89(1):168&#x2013;78. </span></p>
<p style="top:296.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/j. 1471- 4159. 2004. 02319.x</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:306.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 48. L&#xfc;tbow MM, Oerter S, Quader S, Jeanclos E, Cubukova A, Krafft </span></p>
<p style="top:316.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">M, et&#xa0;al. In&#xa0;vitro blood-brain barrier permeability and cytotoxicity </span></p>
<p style="top:326.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of an atorvastatin-loaded nanoformulation against glioblastoma in </span></p>
<p style="top:336.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2D and 3D models. Mol Pharm. 2020;17(6):1835&#x2013;47. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:346.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1021/ acs. molph armac eut. 9b011 17</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:356.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 49. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a </span></p>
<p style="top:366.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">target for brain cancer therapy: synergistic activity of lovastatin </span></p>
<p style="top:376.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and sodium phenylacetate against human glioma cells. J Neu-</span></p>
<p style="top:386.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rochem. 1996;66(2):710&#x2013;6. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1046/j. 1471- 4159. </span></p>
<p style="top:396.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">1996. 66020 710.x</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:406.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 50. Rattan R, Giri S, Singh AK, Singh I. Rho/ROCK pathway as a tar-</span></p>
<p style="top:416.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">get of tumor therapy. J Neurosci Res. 2006;83(2):243&#x2013;55. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:426.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1002/ jnr. 20707</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:436.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 51. Samiei E, Seyfoori A, Toyota B, Ghavami S, Akbari M. Investi-</span></p>
<p style="top:446.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">gating Programmed Cell Death and Tumor Invasion in a Three-</span></p>
<p style="top:456.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Dimensional (3D) Microfluidic Model of Glioblastoma. Int J Mol </span></p>
<p style="top:466.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Sci. 2020;21(9):3162. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3390/ ijms2 10931 62</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:476.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 52. Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M. </span></p>
<p style="top:486.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Lovastatin and phenylacetate induce apoptosis, but not differ-</span></p>
<p style="top:496.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">entiation, in human malignant glioma cells. Acta Neuropathol. </span></p>
<p style="top:506.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2001;101(3):217&#x2013;24. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s0040 10000 254</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:516.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 53. Shojaei S, Koleini N, Samiei E, Aghaei M, Cole LK, Alizadeh J, </span></p>
<p style="top:526.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0;al. Simvastatin increases temozolomide-induced cell death by </span></p>
<p style="top:536.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">targeting the fusion of autophagosomes and lysosomes. FEBS J. </span></p>
<p style="top:546.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2020;287(5):1005&#x2013;34. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/ febs. 15069</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:556.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 54. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, </span></p>
<p style="top:566.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Magrassi L, et&#xa0;al. In&#xa0;vivo enhanced antitumor activity of car-</span></p>
<p style="top:576.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mustine [N, N&#x2019;-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. </span></p>
<p style="top:586.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Cancer Res. 1995;55(3):597&#x2013;602.</span></p>
<p style="top:596.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 55. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fuma-</span></p>
<p style="top:606.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">galli R. Simvastatin, an inhibitor of cholesterol biosynthesis, </span></p>
<p style="top:616.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">shows a synergistic effect with N, N&#x2019;-bis(2-chloroethyl)-N-nitro-</span></p>
<p style="top:626.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sourea and beta-interferon on human glioma cells. Cancer Res. </span></p>
<p style="top:636.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">1992;52(16):4348&#x2013;55.</span></p>
<p style="top:646.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 56. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fuma-</span></p>
<p style="top:656.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">galli R. Simvastatin, a blocker of cholesterol-biosynthesis inhibits </span></p>
<p style="top:666.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">human glioma cell-proliferation. Neuro Oncol. 1991;66:121&#x2013;5. </span></p>
<p style="top:676.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ 978- 94- 011- 3152-0_ 22</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:686.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 57. Staedler D, Chapuis-Bernasconi C, Dehmlow H, Fischer H, </span></p>
<p style="top:696.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Juillerat-Jeanneret L, Aebi JD. Cytotoxic effects of combination </span></p>
<p style="top:706.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of oxidosqualene cyclase inhibitors with atorvastatin in human </span></p>


<p style="top:32.4pt;left:532.1pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">309</span></p>
<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">Statins and Gliomas</span></p>
<p style="top:56.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cancer cells. J Med Chem. 2012;55(11):4990&#x2013;5002. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:66.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1021/ jm300 256z</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:76.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 58. Tapia-P&#xe9;rez JH, Kirches E, Mawrin C, Firsching R, Sch-</span></p>
<p style="top:86.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">neider T. Cytotoxic effect of different statins and thiazoli-</span></p>
<p style="top:96.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">dinediones on malignant glioma cells. Cancer Chemother </span></p>
<p style="top:106.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Pharmacol. 2011;67(5):1193&#x2013;201. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:116.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s00280- 010- 1535-2</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:126.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 59. Tsuboi Y, Kurimoto M, Nagai S, Hayakawa Y, Kamiyama H, </span></p>
<p style="top:136.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Hayashi N, et&#xa0;al. Induction of autophagic cell death and radio-</span></p>
<p style="top:146.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sensitization by the pharmacological inhibition of nuclear fac-</span></p>
<p style="top:156.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tor-kappa B activation in human glioma cell lines. J Neurosurg. </span></p>
<p style="top:166.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2009;110(3):594&#x2013;604. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3171/ 2008.8. JNS17 648</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:176.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 60. Yamamoto Y, Tomiyama A, Sasaki N, Yamaguchi H, Shirakihara </span></p>
<p style="top:186.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">T, Nakashima K, et&#xa0;al. Intracellular cholesterol level regulates sen-</span></p>
<p style="top:196.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">sitivity of glioblastoma cells against temozolomide-induced cell </span></p>
<p style="top:206.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">death by modulation of caspase-8 activation via death receptor </span></p>
<p style="top:216.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">5-accumulation and activation in the plasma membrane lipid raft. </span></p>
<p style="top:226.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Biochem Biophys Res Commun. 2018;495(1):1292&#x2013;9. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:236.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1016/j. bbrc. 2017. 11. 113</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:246.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 61. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dra-</span></p>
<p style="top:256.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matic synergistic anticancer effect of clinically achievable doses </span></p>
<p style="top:266.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of lovastatin and troglitazone. Int J Cancer. 2006;118(3):773&#x2013;9. </span></p>
<p style="top:276.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ ijc. 21361</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:286.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 62. Zhu Z, Zhang P, Li N, Kiang KMY, Cheng SY, Wong VKW, </span></p>
<p style="top:296.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0;al. Lovastatin enhances cytotoxicity of temozolomide via </span></p>
<p style="top:306.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">impairing autophagic flux in glioblastoma cells. Biomed Res Int. </span></p>
<p style="top:316.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2019;2019:2710693. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1155/ 2019/ 27106 93</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:326.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 63. Dastghabi A, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson </span></p>
<p style="top:336.5pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">JB, Samali A, et&#xa0;al. Simvastatin induces unfolded protein response </span></p>
<p style="top:346.5pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">and enhances temozolomide-induced cell death in glioblastoma </span></p>
<p style="top:356.5pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">cells. Cells. 2020;9(11):2339. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 3390/ cells 91123 </span></p>
<p style="top:366.5pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">39</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:376.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 64. Gabrys D, D&#xf6;rfler A, Yaromina A, Hessel F, Krause M, Oer-</span></p>
<p style="top:386.5pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tel R, et&#xa0;al. Effects of lovastatin alone or combined with irra-</span></p>
<p style="top:396.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">diation on tumor cells in&#xa0;vitro and in&#xa0;vivo. Strahlenther Onkol. </span></p>
<p style="top:406.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2008;184(1):48&#x2013;53. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s00066- 008- 1805-7</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:416.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 65. Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino </span></p>
<p style="top:426.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">S, et&#xa0;al. Novel anti-glioblastoma agents and therapeutic combina-</span></p>
<p style="top:436.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tions identified from a collection of FDA approved drugs. J Transl </span></p>
<p style="top:446.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Med. 2014;12:13. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1186/ 1479- 5876- 12- 13</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:456.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 66. Kikuchi T, Nagata Y, Abe T. In&#xa0;vitro and in&#xa0;vivo antiprolifera-</span></p>
<p style="top:466.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tive effects of simvastatin, an HMG-CoA reductase inhibitor, on </span></p>
<p style="top:476.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">human glioma cells. J Neurooncol. 1997;34(3):233&#x2013;9. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:486.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1023/a: 10057 53523 949</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:496.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 67. Kula M, Tanriverdi G, Oksuz E, Bilir A, Shahzadi A, Yazici Z. </span></p>
<p style="top:506.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Simvastatin and dexamethasone potentiate antitumor activity of </span></p>
<p style="top:516.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fotemustine. Int J Pharmacol. 2014;10(5):267&#x2013;74. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:526.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 3923/ ijp. 2014. 267. 274</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:536.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 68. Liu PC, Lu G, Deng Y, Wang CD, Su XW, Zhou JY, et&#xa0;al. Inhi-</span></p>
<p style="top:546.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">bition of NF-&#x3ba;B pathway and modulation of MAPK signaling </span></p>
<p style="top:556.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">pathways in glioblastoma and implications for lovastatin and </span></p>
<p style="top:566.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tumor necrosis factor-related apoptosis inducing ligand (TRAIL) </span></p>
<p style="top:576.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">combination therapy. PLoS ONE. 2017;12(1): e0171157. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// </span></p>
<p style="top:586.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">doi. org/ 10. 1371/ journ al. pone. 01711 57</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:596.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 69. Peng P, Wei W, Long C, Li J. Atorvastatin augments temozo-</span></p>
<p style="top:606.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lomide&#x2019;s efficacy in glioblastoma via prenylation-dependent </span></p>
<p style="top:616.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">inhibition of Ras signaling. Biochem Biophys Res Commun. </span></p>
<p style="top:626.4pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2017;489(3):293&#x2013;8. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. bbrc. 2017. 05. 147</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:636.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 70. Tapia-P&#xe9;rez JH, Preininger R, Kirches E, Reinhold A, Butzmann J, </span></p>
<p style="top:646.3pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Prilloff S, et&#xa0;al. Simultaneous administration of statins and piogl-</span></p>
<p style="top:656.3pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">itazone limits tumor growth in a rat model of malignant glioma. </span></p>
<p style="top:666.3pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Anticancer Res. 2016;36(12):6357&#x2013;65. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 21873/ </span></p>
<p style="top:676.3pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">antic anres. 11233</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:686.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 71. Bababeygy SR, Polevaya NV, Youssef S, Sun A, Xiong A, Prugpi-</span></p>
<p style="top:696.3pt;left:68.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">chailers T, et&#xa0;al. HMG-CoA reductase inhibition causes increased </span></p>
<p style="top:56.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">necrosis and apoptosis in an in&#xa0;vivo mouse glioblastoma multi-</span></p>
<p style="top:66.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">forme model. Anticancer Res. 2009;29(12):4901&#x2013;8.</span></p>
<p style="top:76.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 72. Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, </span></p>
<p style="top:86.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Fogal V, et&#xa0;al. In&#xa0;vitro and in&#xa0;vivo anticancer effects of meva-</span></p>
<p style="top:96.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">lonate pathway modulation on human cancer cells. Br J Cancer. </span></p>
<p style="top:106.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2014;111(8):1562&#x2013;71. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1038/ bjc. 2014. 431</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:116.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 73. Murakami M, Goto T, Saito Y, Goto S, Kochi M, Ushio Y. The </span></p>
<p style="top:126.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">inhibitory effect of simvastatin on growth in malignant gliomas&#x2013;</span></p>
<p style="top:136.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">with special reference to its local application with fibrin glue </span></p>
<p style="top:146.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">spray in&#xa0;vivo. Int J Oncol. 2001;19(3):525&#x2013;31. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:156.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 3892/ ijo. 19.3. 525</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:166.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 74. Wang X, Huang Z, Wu Q, Prager BC, Mack SC, Yang K, et&#xa0;al. </span></p>
<p style="top:176.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">MYC-Regulated Mevalonate Metabolism Maintains Brain </span></p>
<p style="top:186.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Tumor-Initiating Cells. Cancer Res. 2017;77(18):4947&#x2013;60. </span></p>
<p style="top:196.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1158/ 0008- 5472. CAN- 17- 0114</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:206.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 75. Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez </span></p>
<p style="top:216.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">I, et&#xa0;al. Statins affect human glioblastoma and other cancers </span></p>
<p style="top:226.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">through TGF-&#x3b2; inhibition. Oncotarget. 2019;10(18):1716&#x2013;28. </span></p>
<p style="top:236.3pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 18632/ oncot arget. 26733</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:246.3pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 76. Chen BK, Chiu HF, Yang CY. Statins are associated with a </span></p>
<p style="top:256.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reduced risk of brain cancer: a population-based case-control </span></p>
<p style="top:266.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">study. Medicine (Baltimore). 2016;95(17): e3392. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:276.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1097/ MD. 00000 00000 003392</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:286.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 77. Seliger C, Meier CR, Becker C, Jick SS, Bogdahn U, Hau P, </span></p>
<p style="top:296.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0;al. Statin use and risk of glioma: population-based case-con-</span></p>
<p style="top:306.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">trol analysis. Eur J Epidemiol. 2016;31(9):947&#x2013;52. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:316.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1007/ s10654- 016- 0145-7</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:326.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 78. Cote DJ, Smith-Warner SA, Creed JH, Furtado J, Gerke T, Wang </span></p>
<p style="top:336.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">M, et&#xa0;al. Circulating lipids and glioma risk: results from the </span></p>
<p style="top:346.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">UK Biobank, Nurses&#x2019; Health Study, and Health Professionals </span></p>
<p style="top:356.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Follow-Up Study. Cancer Causes Control. 2021;32(4):347&#x2013;55. </span></p>
<p style="top:366.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s10552- 021- 01391-8</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:376.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 79. Cote DJ, Rosner BA, Smith-Warner SA, Egan KM, Stamp-</span></p>
<p style="top:386.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">fer MJ. Statin use, hyperlipidemia, and risk of glioma. Eur J </span></p>
<p style="top:396.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Epidemiol. 2019;34(11):997&#x2013;1011. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ </span></p>
<p style="top:406.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">s10654- 019- 00565-8</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:416.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 80. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA </span></p>
<p style="top:426.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. </span></p>
<p style="top:436.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2012;131(6):E1031-1037. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1002/ ijc. 27536</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:446.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 81. Bhavsar S, Hagan K, Arunkumar R, Potylchansky Y, Grasu R, </span></p>
<p style="top:456.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Dang A, et&#xa0;al. Preoperative statin use is not associated with </span></p>
<p style="top:466.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">improvement in survival after glioblastoma surgery. J Clin Neu-</span></p>
<p style="top:476.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">rosci. 2016;31:176&#x2013;80. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. jocn. 2016. 03. </span></p>
<p style="top:486.2pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">010</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:496.2pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 82. Gaist D, Hallas J, Friis S, Hansen S, S&#xf8;rensen HT. Statin use and </span></p>
<p style="top:506.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">survival following glioblastoma multiforme. Cancer Epidemiol. </span></p>
<p style="top:516.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2014;38(6):722&#x2013;7. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1016/j. canep. 2014. 09. 010</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:526.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 83. Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hick-</span></p>
<p style="top:536.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ing C, et&#xa0;al. Do statins, ACE inhibitors or sartans improve out-</span></p>
<p style="top:546.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">come in primary glioblastoma? J Neurooncol. 2018;138(1):163&#x2013;</span></p>
<p style="top:556.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">71. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s11060- 018- 2786-8</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:566.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 84. Seliger C, Schaertl J, Gerken M, Luber C, Proescholdt M, Rie-</span></p>
<p style="top:576.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">menschneider MJ, et&#xa0;al. Use of statins or NSAIDs and survival </span></p>
<p style="top:586.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">of patients with high-grade glioma. PLoS ONE. 2018;13(12): </span></p>
<p style="top:596.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">e0207858. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1371/ journ al. pone. 02078 58</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:606.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 85. Henker C, Kriesen T, Scherer M, Glass A, von Deimling A, Bend-</span></p>
<p style="top:616.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">szus M, et&#xa0;al. Association between tumor compartment volumes, </span></p>
<p style="top:626.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">the incidence of pretreatment seizures, and statin-mediated protec-</span></p>
<p style="top:636.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tive effects in glioblastoma. Neurosurgery. 2019;85(4):E722&#x2013;9. </span></p>
<p style="top:646.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1093/ neuros/ nyz079</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:656.1pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 86. Altwairgi AK, Alghareeb WA, AlNajjar FH, Alhussain H, Alsaeed </span></p>
<p style="top:666.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">E, Balbaid AAO, et&#xa0;al. Atorvastatin in combination with radio-</span></p>
<p style="top:676.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">therapy and temozolomide for glioblastoma: a prospective phase </span></p>
<p style="top:686.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">II study. Invest New Drugs. 2021;39(1):226&#x2013;31. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ </span></p>
<p style="top:696.1pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">10. 1007/ s10637- 020- 00992-5</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>


<p style="top:32.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt"> 310</span></p>
<p style="top:32.4pt;left:488.2pt;line-height:8.5pt"><span style="font-family:MyriadPro,serif;font-size:8.5pt">L.&#xa0;F.&#xa0;Rendon et al.</span></p>
<p style="top:56.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 87. Mohebbi N, Khonshnevisan A, Naderi S, Abdollahzade S, Sala-</span></p>
<p style="top:66.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">mzadeh J, Javadi M, et&#xa0;al. Effects of atorvastatin on plasma </span></p>
<p style="top:76.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">matrix metalloproteinase-9 concentration after glial tumor resec-</span></p>
<p style="top:86.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tion; a randomized, double blind, placebo-controlled trial. Daru. </span></p>
<p style="top:96.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2014;22(1):10. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1186/ 2008- 2231- 22- 10</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:106.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 88. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, </span></p>
<p style="top:116.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">et&#xa0;al. DrugBank 5.0: a major update on the DrugBank database </span></p>
<p style="top:126.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">for 2018. Nucleic Acid Res. 2018;46(D1):D1074&#x2013;82. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:136.6pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1093/ nar/ gkx10 37</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:146.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 89. Wood WG, Eckert GP, Igbavboa U, M&#xfc;ller WE. Statins and neu-</span></p>
<p style="top:156.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">roprotection: a prescription to move the field forward. Ann N Y </span></p>
<p style="top:166.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Acad Sci. 2010;1199:69&#x2013;76. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1111/j. 1749- 6632. </span></p>
<p style="top:176.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">2009. 05359.x</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:186.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 90. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravasta-</span></p>
<p style="top:196.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">tin and lovastatin in cerebrospinal fluid in healthy subjects. Clin </span></p>
<p style="top:206.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">Neurooharmacol. 1991;14(3):256&#x2013;61. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1097/ </span></p>
<p style="top:216.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">00002 826- 19910 6000- 00010</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:226.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 91. Wood WG, M&#xfc;ller WE, Eckert GP. Statins and neuroprotection: </span></p>
<p style="top:236.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">basic pharmacology needed. Mol Neurobiol. 2014;50(1):214&#x2013;20. </span></p>
<p style="top:246.5pt;left:68.0pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1007/ s12035- 014- 8647-3</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:56.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 92. Danaei G, Tavakkoli M, Hern&#xe1;n MA. Bias in observational </span></p>
<p style="top:66.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">studies of prevalent users: lessons for comparative effective-</span></p>
<p style="top:76.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">ness research from a meta-analysis of statins. Am J Epidemiol. </span></p>
<p style="top:86.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">2012;175(4):250&#x2013;62. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1093/ aje/ kwr301</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:96.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 93. Mansournia MA, Etminan M, Danaei G, Kaufman JS, Collins </span></p>
<p style="top:106.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">G. Handling time varying confounding in observational research. </span></p>
<p style="top:116.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">BMJ. 2017;359: j4587. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1136/ bmj. j4587</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:126.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 94. Cole SR, Hern&#xe1;n MA. Constructing inverse probability weights for </span></p>
<p style="top:136.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">marginal structural models. Am J Epidemiol. 2008;168(6):656&#x2013;</span></p>
<p style="top:146.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">64. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. org/ 10. 1093/ aje/ kwn164</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:156.5pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 95. Oxford Centre for Evidence-Based Medicine.&#xa0;</span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// www. cebm. </span></p>
<p style="top:166.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">ox. ac. uk/ resou rces/ levels- of- evide nce/ ocebm- levels- of- evide nce</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>
<p style="top:176.5pt;left:306.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt"> 96. Xie Y, Lu Q, Lenahan C, Yang S, Zhou D, Qi X. Whether statin </span></p>
<p style="top:186.5pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">use improves the survival of patients with glioblastoma? A meta-</span></p>
<p style="top:196.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt">analysis. Medicine (Baltimore). 2020;99(9): e18997. </span><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">https:// doi. </span></p>
<p style="top:206.4pt;left:323.2pt;line-height:8.5pt"><span style="font-family:STIX,serif;font-size:8.5pt;color:#0000ff">org/ 10. 1097/ MD. 00000 00000 018997</span><span style="font-family:STIX,serif;font-size:8.5pt">.</span></p>

</div>
